 
 
 
 
 
 
 
 
NIRTRAKS – (NIRxcell TRial for a post mArKet Study)  
 
 
 
Clinical Protocol 
NIRxcell™ Stent System 
  
Study Number: CV103-02  
 
 
 
 
 
 
Revision history: 
Document #/Version/Date: CV103-02/ Version 1.2 / 03 March 2015 
Amended:  
Administrative Change: N/A 
 
 
CONFIDENTIAL  DO NOT COPY 
 
This clinical protocol cont ains confidential information for use by [CONTACT_592515].  It should be held confidential and maintained in a secure location.  It should 
not be copi[INVESTIGATOR_592487].   
 
NIRxcell™ is a trademark of Medinol Ltd., Israel.   
  
The protocol was developed in collaboration between Harvard Clinical Research Institute and Medinol. 
 

Medinol Confidential 
[ADDRESS_781427]-Market Study Protocol # CV103-02 Page 2 of 72 
Version 1.2 NIRTRAKS –(NIRxcell TRial for a post mArKet Study) – Protocol Signature [CONTACT_592554]: ______________________________ 
 
Investigator’s Responsibility  
 
Prior to enrolling subjects in the NIRTRAKS Post-Market Study, the principal investigator [INVESTIGATOR_592488]/her Institutional Review Board (IRB).  This approval must be in the principal investigator’s name [INVESTIGATOR_1238] a copy se nt to Medinol, among other essential documents, 
along with the IRB-approved informed consent and the signed clinical trial agreement.  
Additionally, the principal investigator  [INVESTIGATOR_592489]:  
 
I have read this protocol and agree to adhere to  the requirements.  I will provide copi[INVESTIGATOR_592490].  I will discuss 
this material with them and ensure they ar e fully informed regarding the investigational 
product and the conduct of the study. 
 
 
 Date:  
Principal Investigator’s Signature  
  
  
[INVESTIGATOR_678]’s Printed Name  
  
  
 [CONTACT_1782]:  
Sub- Investigator’s Signature  
  
  
[INVESTIGATOR_678]’s Printed Name  
 
 
  
  
[CONTACT_592555] # 
 
  
Medinol Confidential 
[ADDRESS_781428]-Market Study Protocol # CV103-[ADDRESS_781429]-2014 Initial Release 
1.1 
To the FDA 12-Jan-2015 Revisions made per FDA's requirements, as well as few 
corrections/clarifications added to the previous protocol version.  
See detailed list of changes below. 
1.2 
To the FDA 03-Mar-2015 Revisions made per FDA's requirements presented in the letter dated 
[ADDRESS_781430] of major changes versus Protocol ver. 1.1: 
 
Section (in 1.1 version)  Revisions   Rationale  
4.2 – Secondary  Endpoints  Addition of a secondary  endpoint 
of TVF at 9 months Medinol’s  answer to Q1 FDA 
letter dated Feb. 3, 2015 
4.2.4 – All Cause MI at 30 Days, 
and 1, 2 and 3 Years Deletion of wording due to change 
of MI definition  Medinol’s  answer to Q3 FDA 
letter dated Feb. 3, 2015 
5.0 – Study Design Addition of 9 months follow‐up 
(FU) Medinol’s  answer to Q1 FDA 
letter dated Feb. 3, 2015 
7.0 – Treatment  Methodology   Clarification  that post procedure  
cardiac biomarkers  will be 
routinely measured  in all subjects Medinol’s  answer to Q2 FDA 
letter dated Feb. 3, 2015 
9.0 – Follow‐Up Assessments   Addition of a follow‐up telephone  
contact [INVESTIGATOR_136] 9 months Medinol’s  answer to Q1 FDA 
letter dated Feb. 3, 2015 
9.0 – Follow‐Up Assessments  Clarification  that post procedure  
cardiac biomarkers  will be 
routinely measured  in all subjects Medinol’s  answer to Q2 FDA 
letter dated Feb. 3, 2015 
12.1 – Determination  of 
Performance  Metrics Removal of the adjustment  for 
non‐clinically relevant 
periprocedural  MI Medinol’s  answer to Q3 FDA 
letter dated Feb. 3, [ADDRESS_781431]‐procedure  cardiac 
biomarkers  will be routinely 
collected in all subjects as 
was done in the reference  
studies. Therefore,  there is 
no need to adjust the 
periprocedural  MI rates in 
the reference  studies. 
Medinol Confidential 
[ADDRESS_781432]-Market Study Protocol # CV103-02 Page 4 of 72 
Version 1.2 12.1 – Determination  of 
Performance  Metrics 
Table [ADDRESS_781433] the removal of 
the adjustment  for non‐clinically 
relevant periprocedural  MI Medinol’s  answer to Q3 FDA 
letter dated Feb. 3, 2015 
12.1 – Determination  of 
Performance  Metrics Updating the meta‐analysis rate of 
3‐year TVF to 23.2% Medinol’s  answer to Q3 FDA 
letter dated Feb. 3, 2015 
 
Following  the removal of the 
adjustment  for non‐clinically 
relevant periprocedural  MI 
and the updated TVF rates in 
Table 5. 
12.2 – Performance  Goal  Updating the performance  goal to 
34.8% Medinol’s  answer to Q1 FDA 
letter dated Feb. 3, [ADDRESS_781434] the updated meta‐
analysis rate 
12.3 – Primary Endpoint and 
Sample Size Calculation  Updating the power to 83% Medinol’s  answer to Q1 FDA 
letter dated Feb. 3, [ADDRESS_781435] the  updated 
meta‐analysis rate and 
updated performance  goal 
12.7 – Analysis of Primary 
Endpoint Updating the performance  goal to 
34.8% Medinol’s  answer to Q1 FDA 
letter dated Feb. 3, 2015 
12.9 – Analysis of secondary  
endpoint Addition of TVF at 9 months Per Medinol’s  response to 
FDA's Q1 
16.2 – Sponsor’s  Responsibilities  
for Preparing  and Submitting  
Reports Updating the timelines for 
submission  of PAS Progress 
Reports Medinol’s  answer to Q4 FDA 
letter dated Feb. 3, 2015 
Appendix  1‐P Study Definitions  –
MI definition   Updating the definition  of 
periprocedural  MI to follow the 
ARC definition  rather than the new 
definition  of clinically relevant MI Medinol’s  answer to Q3 FDA 
letter dated Feb. 3, 2015 
Editorial/minor  corrections  
throughout  the protocol    
 
Medinol Confidential 
[ADDRESS_781436]-Market Study Protocol # CV103-02 Page 5 of 72 
Version 1.2 Table of Contents : 
 
NIRTRAKS –(NIRXCELL TRIAL FOR A POST MARKET STUDY)– PROTOCOL SIGNATURE [CONTACT_1783] .. 2  
PROTOCOL SUMMARY .............................................................................................................. ............................ 7  
1  INTRODUCTION AND RATIONALE .................................................................................................... ..... 13 
2  DEVICE DESCRIPTION AND INTENDED USE .... ................................................................................... 15  
2.1 DEVICE DESCRIPTION  .............................................................................................................................. ...... 15 
2.2 INTENDED USE OF THE DEVICE  ...................................................................................................................... 16  
3  PURPOSE AND OBJECTIVES .................... .................................................................................... ............. 17  
4  ENDPOINTS ..................................................................................................................... ............................... 18  
4.1 PRIMARY ENDPOINT  .............................................................................................................................. ......... 18 
4.2 SECONDARY ENDPOINTS  .............................................................................................................................. .. 18 
4.2.1 TVF  AT 9 MONTHS  .............................................................................................................................. ...... 18 
4.2.2 ALL CAUSE DEATH AT 30 DAYS, AND 1, 2 AND 3 YEARS  .......................................................................... 18  
5  STUDY DESIGN .................... .......................... .......................... ......................... ................. ............................ 20  
5.1 CONTROL OF SYSTEMATIC ERROR /BIAS ........................................................................................................ [ADDRESS_781437] SCREENING /ASSESSMENT  ................................................................................................................ [ADDRESS_781438]-PROCEDURE ASSESSMENT (HOSPI[INVESTIGATOR_440100] ) ............................................................................. 29  
8  CONCOMITANT MEDICATIONS .................... ................................................................................... ....... 30 
9  FOLLOW-UP ASSESSMENTS.. .......................... .......................... .......................... .......................... ............ 31 
9.1 30-D AY (±2 WEEKS ) CONTACT  ...................................................................................................................... 31  
9.2 9-M ONTH (±1 MONTH ) CONTACT  .................................................................................................................. 31  
9.3 1-Y EAR (±1 MONTH ) CONTACT  ..................................................................................................................... 31  
9.4 2-Y EAR (±1 MONTH ) CONTACT  ..................................................................................................................... 31  
9.5 3-Y EARS (±1 MONTH ) CONTACT  ................................................................................................................... 31  
9.6 UNSCHEDULED VISIT /PHONE FOLLOW UP  ....................................................................................................... [ADDRESS_781439]-Market Study Protocol # CV103-[ADDRESS_781440]  ............................................................................................................... 53  
15.3 INFORMED CONSENT FORM ....................................................................................................................... 53  
15.4 CONFIDENTIALITY  .............................................................................................................................. ....... 54 
16 REPORTING REQUIREMEN TS ........................................................................................................ .......... 55 
16.1 INVESTIGATOR REPORTING RESPONSIBILITIES  .......................................................................................... 55  
16.2 SPONSOR REPORTING REQUIREMENTS  ...................................................................................................... 56  
17 REFERENCES .................................................................................................................... ............................. 58  
Appendix 1-P: Study Definitions ............................................................................................... ......................... [ADDRESS_781441]-Market Study Protocol # CV103-[ADDRESS_781442]-Market Study  
DEVICE (S) NIRxcell™  CoCr Coronary Stent on RX  System (NIRxcell™ Stent 
System) 
REGULATORY 
STATUS  Approved device: FDA approved (PMA# P110004/S001); CE marking 
since May 31, 2013; Israeli registration number [ADDRESS_781443]-marketing, non-randomized, multi-center, 
single-arm clinical study that will be conducted at up to 15 sites in the 
[LOCATION_002] (US). All subjects will be treated with the NIRxcell Stent 
System and followed at [ADDRESS_781444]–index stenting procedure. An unscheduled follow up may be conducted 
as clinically warranted.  
OBJECTIVE  The main objective of this study is to collect and analyze additional 
information about the safety and e ffectiveness of the NIRxcell Stent 
System in the treatment of de novo  stenotic lesions in native coronary 
arteries in the US population. The primary endpoint will be the rate of 
target vessel failure (TVF) at 3 y ears of treatment with the NIRxcell 
Stent System. This rate will be co mpared with a performance goal 
derived from a meta-analysis of coronary stenting with bare metal 
stents (BMS).  
STUDY HYPOTHESIS  Medinol NIRTRAKS Post-Market Study will have a primary endpoint 
(TVF) rate less than 34.8% at 3 years, and by [CONTACT_592516]. 
NUMBER OF 
SUBJECTS  131 subjects will be enrolled to ac count for loss to follow-up, which is 
conservatively estimated at approximately 7.0% per year (resulting in 105 evaluable subjects), at up to 15 sites in the US. 
PRIMARY ENDPOINT  Target vessel failure , defined as a composite of cardiac death, target 
vessel myocardial infarction (MI), or  clinically driven target vessel 
revascularization (TVR) by [CONTACT_592517] [ADDRESS_781445]-Market Study Protocol # CV103-02 Page 8 of 72 
Version 1.2 SECONDARY 
ENDPOINTS (CONT.) 2. All-cause death at 30 days, and 1, 2 and 3 years. 
3. Cardiac death at 30 days, and 1, 2 and 3 years. 
4. All cause MI  at 30 days, and 1, 2 and 3 years. 
5. Target vessel MI  at 30 days, and 1, 2 and 3 years. 
6. Clinically driven target lesion revascularization (TLR) 
at 30 days, and 1, 2 and 3 years. 
7. Clinically driven TVR at 30 days, and 1, 2 and 3 years. 
8. Acute success  rates   
a. Device success : Attainment of <50% final 
residual stenosis of th e target lesion using 
only the NIRxcell Stent System. 
b. Lesion Success : Attainment of <50% final 
residual stenosis of the target lesion using any percutaneous method. 
c. Procedure Success : Attainment of <50% 
residual stenosis of the target lesion and no in-hospi[INVESTIGATOR_39473], MI, or TLR.  
9. Stent thrombosis at hospi[INVESTIGATOR_2345], [ADDRESS_781446] 
POPULATION  Subjects with symptomatic ischemic heart disease due to a single de 
novo  stenotic lesion contained within  a native coronary  artery with a 
reference vessel diameter between 2.5 mm and 4.0 mm and lesion length ≤30 mm that is amenable to perc utaneous revascularization with 
stent deployment. 
SAMPLE SIZE 
CONSIDERATIONS   3-year TVF rate for BMS derived from the meta-analysis is 
23.2% (95% CI 19.8%, 26.7%). 
 Performance goal for BMS = 34.8%.  
 Type I error ( α) = 0.05 (one-sided). 
 Statistical power (1 – β) = 83%%. 
 Expected 3-year TVF rate for NIRxcell Stent System = 23.2%. 
An evaluable sample size of 105 provides 83% power to demonstrate 
that NIRxcell Stent System meets the performance goal for TVF. Thus, 
131 subjects will be enrolled to ac count for loss to follow-up, which is 
conservatively estimated at approximately 7% per year. 
Medinol Confidential 
[ADDRESS_781447]-Market Study Protocol # CV103-[ADDRESS_781448] is ≥[ADDRESS_781449] is eligible for percutaneo us coronary intervention (PCI). 
3. Subject is eligible for dual anti-platelet therapy (DAPT) with aspi[INVESTIGATOR_592491], prasugrel or ticagrelor for a minimum of [ADDRESS_781450] is an acceptable candidate for coronary artery by[CONTACT_9292] 
(CABG) surgery. 
7. Subject has stable angina pectoris (Canadian Cardiovascular 
Society Classification [CCSC] 1, 2, 3 or 4) or unstable angina pectoris (Braunwald Class 1-3,  B-C) or a positive functional 
ischemia study (e.g. exercise to lerance test [ETT], single-photon 
emission computerized to mography [SPECT], stress 
echocardiography or cardiac computerized tomography [CT]). 
8. Female subjects of child bearing potential must have a negative 
pregnancy test within [ADDRESS_781451] is indicated for elective stenting of a single stenotic lesion 
in a native co ronary artery. 
2. Reference vessel 
≥2.5 mm and ≤4.0 mm in diameter by [CONTACT_306060]. 
3. Target lesion ≤30 mm in length by [CONTACT_13729] (the intention 
should be to cover the whole lesion with 1 stent of adequate length). 
4. Target lesion stenosis ≥50% and <100% by [CONTACT_13729].  
Medinol Confidential 
[ADDRESS_781452]-Market Study Protocol # CV103-[ADDRESS_781453]-procedure. 
6. The target lesion requires treatment with a device other than 
percutaneous transluminal coronary angioplasty (PTCA) prior to 
stent placement (such as, but not limited to, directional coronary 
atherectomy, excimer laser, rotational atherectomy, etc.). 
7. Previous drug-eluting stent (DES) deployment anywhere in the 
target vessel. 
8. Any previous DES deployment within the past 12 months. 
9.  Any previous stent placement with in 15 mm proximal or distal 
to the target lesion. 
10. Co-morbid condition(s) that coul d limit the subject’s ability to 
participate in the trial or to co mply with follow-up requirements, 
or impact the scientific integrity of the trial. 
11. Concurrent medical condition with a life expectancy of <3 years. 
12. Documented left ventricular ejection fraction (LVEF) <25% at 
the most recent evaluation. 
13. Evidence of an acute MI within 72 hours of the intended index 
procedure. 
14. History of cerebrovascular accident or transient ischemic attack 
within 6 months prior to the index procedure. 
15. Leukopenia (leukocytes <3.5  10
9/liter). 
16. Neutropenia (absolute neutrophil count <1,000/mm3) ≤ within 7 
days prior to enrollment. 
17. Thrombocytopenia (platelets <100,000/mm3) pre-procedure 
(within 7 days prior to enrollment). 
18. Active peptic ulcer or active gastrointestinal (GI) bleeding. 
Medinol Confidential 
[ADDRESS_781454]-Market Study Protocol # CV103-02 Page 11 of 72 
Version 1.2 EXCLUSION 
CRITERIA (CONT.) 
 19. Subjects who are ineligible for ≥[ADDRESS_781455] media which 
cannot be adequately pre-medicated. 
21.  Serum creatinine level >2.5 mg/d L within [ADDRESS_781456]-Market Study. 
Angiographic Exclusion Criteria  
1. Unprotected left main coronary artery disease (obstruction >50% 
in the left main co ronary artery that is not protected by ≥1 non-
obstructed by[CONTACT_592518] [LAD] or 
left circumflex [LCX] artery or a branch thereof). 
2. Target vessel exhibiting multiple lesions with >60% diameter 
stenosis outside of a range of 5 mm proximal and distal to the target lesion based on visual estimate or on-line quantitative 
coronary angiography (QCA). 
3. Target lesion exhibiting an intr aluminal thrombus (occupying 
>50% of the true lumen diameter) at any time  prior to the start of 
the intervention. 
4. Lesion location that is aorto-ostial or within 5 mm of the origin 
of the LAD or LCX. 
5. Target lesion with side branches >2.0 mm in diameter. 
6. Target lesion involving a bifurcation (either stenosis of both main 
vessel and major branch or stenosis of just major branch). 
7. Target lesion with severe calcification. 
8. Target vessel exhibiting excessive tortuosity that may impede 
stent delivery and deployment at target lesion.  
9. Target lesion that is located in  a native vessel distal to an 
anastomosis with a saphenous vein graft or a left/right internal 
mammary artery (LIMA/RIMA) by[CONTACT_6476]. 
PRINCIPAL 
INVESTIGATOR  [INVESTIGATOR_592492] R. Patel, MD, FACC 
Associate Professor of Medicine 
Division of Cardiology 
Director, Interventional Cardiology and Catheterization Labs Duke University Health System 
Telephone: [PHONE_12279] 
Email: [EMAIL_11295]  
Medinol Confidential 
[ADDRESS_781457]-Market Study Protocol # CV103-[ADDRESS_781458] Clinical Research Institute (HCRI) 
[ADDRESS_781459]: Michal Hershkovitz,  Vice President, Clinical 
Development  & Regulatory Affairs 
Telephone: [PHONE_12280] /ext. 3209, Fax: [PHONE_12281] 
Email: [EMAIL_11296]  
Medinol Confidential 
[ADDRESS_781460]-Market Study Protocol # CV103-02 Page 13 of 72 
Version 1.2 1 Introduction and Rationale 
Coronary artery disease (CAD) is the most common cause of morbidity and mortality in the 
western hemisphere.  Since its introduction, coronary angioplasty has become a widely accepted 
treatment for CAD, providing high procedural  success rates and symptom relief. However, 
coronary angioplasty alone is associated with a high rate of restenosis (30% to 50%), necessitating repeat revascularization procedures.[1] Treatment of CAD has been significantly 
advanced by [CONTACT_592519], particularly with the advent of coronary stents. In 
comparison with angioplasty alone, stents have reduced the incidence of angiographic and 
clinical restenosis, the recurrence of angina, the need for coronary arterial by[CONTACT_9292] (CABG) 
surgery, the need for repeat revascularization, and the occurrence of major adverse cardiac events (MACE).[2-4] This improvement in outcom es ushered in the bare metal stent (BMS) era, 
a variety of which were approved and used during the 1990s. Expanded indications for stenting of more complex lesion subsets (restenosed lesions, long lesions, small vessels, bifurcations, 
saphenous vein graft lesions, chronic total occlusions, acute myocardial infarctions, etc.) led to 
the exponential growth of the use of coronary stents. However, the long-term success of this 
therapy has been limited by [CONTACT_592520]-stent restenosis.[3-6] Despi[INVESTIGATOR_592493] a larger  luminal diameter as compared to angioplasty 
alone, in-stent restenosis occurs within 6 to 9 months after stent placement in 15% to 35% of subjects.[3-6]  
The Food and Drug Administration (FDA) approval of drug-eluting stents (DES), together with 
their positive results seen in subjects, caused  BMS usage to drop precipi[INVESTIGATOR_592494]. However, concern regarding the long-term safety of 
DES, specifically the possibility of an increased frequency of late stent thrombosis relative to 
BMS, tempered the use of DES in favor of BMS beginning in 2007. The incidence of stent 
thrombosis in randomized trials of DES (either paclitaxel-eluting stents or sirolimus-eluting 
stents) was found to be comparable to that of BMS, and ranged from 0.4% to 0.6% at 12 
months.[7-10] Moreover, the observed rate of stent thrombosis in the ‘real-world’ clinical 
setting, where off-label use is common practice, is almost double the rate observed in clinical 
trials.[11] Further complicating matters is that st ent thrombosis in subjects treated with DES can 
occur outside the 30-day period after stent placement typi[INVESTIGATOR_592495]. Several observational studies of subjects treated with DES in the ‘real-world,’ where off-label use approaches 60%,[12, 13] suggested an increased incidence of late stent thrombosis, 
[14] death and myocardial infarction (MI)[15-17] relative to subjects treated with BMS, although 
more recent data suggest otherwise.[18, 19] Based in part on the uncertainty of the relative risks 
of stent thrombosis with  DES versus BMS, BMS continue to be used regularly in the treatment 
of coronary artery disease in routine clinical practice.[20]  
The NIR
® coronary stent has been on the European market since 1996 and on the US market 
since 1998. Its design is characterized by a “closed cell” geometry, which forms the basis for 
continuous support and smooth scaffolding.  This design was improved upon with the 
NIRFLEX™ stent. The NIRFLEX coronary stent was designed to retain the characteristic “closed cell” design of the NIR stent while offering improved flexibility both before and after expansion. This flexibility led to a reduction in trauma after implantation, as demonstrated in 
independent trials in both the [LOCATION_002] and Europe. 
Medinol Confidential 
[ADDRESS_781461]-Market Study Protocol # CV103-02 Page 14 of 72 
Version 1.2 The Presillion™ and Presillion™ plus Stent Systems are a modification of the currently 
approved NIRFLEX Coronary Stent System (C E mark since March 2002). The Presillion and 
Presillion plus Stent Systems are approved devices in Europe and Israel (CE mark since 
March 2008 and May 2009, respectively; Israel i registration numbers 784-0001 and 784-0003, 
respectively). The Presillion plus Stent System  is approved in the US (FDA PMA #P110004) 
and Canada (Health Canada approval #[ZIP_CODE]). The NIRxcell Stent System is an upgraded 
version of the Presillion plus Stent System, FDA approved (PMA# P110004/S001); CE mark 
since May 31, 2013; Israeli registration number 7840404 since March 11, 2014. 
The NIRxcell Stent System is composed of the same L-605 CoCr Presillion stent (known as 
the PI[INVESTIGATOR_592496]), but is mounted on a different, rapid exchange delivery system, with hydrophilic coating, and includes a semi-compliant balloon.  
The raw materials that are used in the manufacture of the NIRxcell Stent System are the same 
as the raw materials used for the manufacture of  the Presillion Stent System. Both systems are 
integrated under the same environmental cond itions using the same processes, with small 
changes in parameter settings that have no influence on the systems’ properties. 
The safety and effectiveness of the Presillion and Presillion plus Stent Systems were evaluated 
in the PI[INVESTIGATOR_592497], a non-ra ndomized, multi-center, prospective, single-arm clinical study 
(clinicaltrials.gov reference # [STUDY_ID_REMOVED]- unpublished data). The study enrolled 278 subjects at 16 sites in Europe ([LOCATION_013], Sweden and Belgium) and Israel. The primary endpoint was the incidence of target vessel failure (TVF), defined as cardiac death, target 
vessel MI (Q wave or non–Q wave), or clinica lly driven target vessel revascularization (TVR) 
by [CONTACT_13724], within 270 days of treatment with the 
Presillion/Presillion plus Stent System. This rate was compared with a performance goal that 
was derived from a meta-analysis of the literature reporting outcomes with approved BMS. The 270-day TVF rate was 8.7% and the upper bound of the exact one-sided 95% confidence 
interval was 12.7%. Since this upper bound was less than the established performance goal of 16.46%, the primary endpoint was considered to have been met. 
The NIRTRAKS Post-Market Study is designed to supplement the post-market requirements 
for the long-term safety and effectiveness of the NIRxcell Stent System in the U Sby [CONTACT_592521] n about the safety and effectiveness of the device in the 
treatment of stenotic lesions in de novo native  coronary arteries in the US population. The 
primary efficacy endpoint will be evaluated by [CONTACT_592522] [ADDRESS_781462]-Market Study Protocol # CV103-02 Page 15 of 72 
Version 1.2 2 Device Description and Intended Use 
2.1 Device Description 
2.1.1 General 
NIRxcell  CoCr Coronary Stent on RX System  (NIRxcell Stent System, P110004/S001) is a 
single-use device designed and manufactured by [CONTACT_592523]. It comprises a balloon-
expandable, intracoronary stent mounted on a rapid-exchange delivery catheter.  
For the purposes of this clinical investigation,  the NIRxcell Stent System is available in 32 
device models to accommodate various reference vessel diameters and lesion lengths. For details refer to Table 1. 
2.1.2 Detailed Information 
NIRxcell Stent System 
The NIRxcell stents are cut from panels of flat sheets of L-605 cobalt-chromium alloy, after 
which the stents are folded into cylinders and welded. The NIRxcell stent geometry is made 
up of alternating wide and narrow struts to enable the stent to be flexible in the unexpanded configuration and to support the vessel, while conforming to its curvature, in the expanded 
configuration. At the distal end of the catheter is a delivery balloon designed to expand to a 
controlled diameter and length when inflated. The balloon delivery catheter has 2 platinum iridium radiopaque marker bands defining the length and location of the mounted stent.  
The usable length of the delivery system is 140 cm with a shaft profile of 2.1F (0.69 mm) / 
2.6F (0.86 mm) (proximal/distal). It has a distal port (hole) approximately 30 cm from the 
distal tip that accesses the guide wire lumen. The guide wire lumen begins at the distal port and terminates at the distal tip. The catheter also has 2 markers on the proximal catheter shaft 
that indicate, approximately, the exit of the ba lloon catheter tip from the guiding catheter 
(brachial: 93 cm; femoral: 103 cm). 
  
Medinol Confidential 
[ADDRESS_781463]-Market Study Protocol # CV103-02 Page 16 of 72 
Version 1.2 Table 1: NIRxcell Stent System: Device  Matrix for NIRTRA KS Post-Market Study  
MODEL  DESCRIPTION  
 
Catalogue 
Number Nominal Stent 
System Size  
Stent 
Labeled 
Diameter 
(mm) Stent 
Labeled 
Length 
(mm) Maximum Post 
Deployment 
Stent Diameter
(mm) Nominal 
Pressure
(Atm) Rated 
Burst 
Pressure 
(Atm) 
NLT Minimum 
Guiding 
Catheter 
Compatibility 
(ID) 
NXL25008US 
2.[ADDRESS_781464] enotic lesions in de novo  native 
coronary arteries (length ≤30 mm) with a reference vessel diameter of 2.[ADDRESS_781465]-Market Study Protocol # CV103-[ADDRESS_781466]–index 
stenting procedure. The primary objective is to compare the incidence of TVF within [ADDRESS_781467]–index stenting procedure as well as a number of secondary outcomes 
will be used to determine the long-term clinic al effectiveness of treating native coronary 
artery lesions with the investigational produc t. TVF was selected as the primary clinical 
outcome to allow for conclusive comparisons of  the efficacy of the NIRxcell Stent System 
with other historical results.  
The NIRTRAKS Post-Market Study will be performed according to the World Medical 
Association Declaration of Helsinki, and FDA regulation 21 CFR parts 803, 812, 50 & 54. The data collected will be used to support the post-market requirements for the NIRxcell Stent 
System.  
Medinol Confidential 
[ADDRESS_781468]-Market Study Protocol # CV103-[ADDRESS_781469]-Market Study.  
4.1 Primary Endpoint 
The primary endpoint for this study is TVF, which is defined as a composite of  cardiac death, 
target vessel MI, or clinically driven TVR by [CONTACT_592524]  
4.2 Secondary Endpoints 
4.2.1 TVF at 9 Months  
4.2.2 All Cause  Death at 30 Days, and 1, 2 and 3 Years 
4.2.3 Cardiac Death at 30 Days, and 1, 2 and 3 Years 
Cardiac death is defined as any death due to proximate cardiac cause (e.g. MI, low-output 
failure, fatal arrhythmia), unwitnessed death and death of unknown cause, and all procedure-
related deaths, including those related to concomitant treatment. 
4.2.4 All Cause MI at 30 Days, and 1, 2 and 3 Years 
4.2.5 MI is defined using the Academic Research Consortium (ARC) definitions (see 
Appendix 1-P).  
4.2.6 Target Vessel MI at 30 Days, and 1, 2 and 3 Years 
Target vessel MI is defined as any MI attributed to the target vessel.   
4.2.7 Clinically Driven TLR at 30 Days, and 1, 2 and 3 Years 
Clinically-driven target lesion revascularization (TLR) is defined as any revascularization at 
the target lesion associated w ith positive functional ischemia st udy or ischemic symptoms and 
an angiographic minimal lumen diameter stenosis 50% by [CONTACT_263510] 
(QCA), or revascularization of a target lesion with diameter stenosis 70% by [CONTACT_592525] a positive functional study. 
4.2.8 Clinically Driven TVR at 30 Days, and 1, 2 and 3 Years 
Clinically-driven TVR is defined as any revasculariz ation in the target vessel that is associated 
with positive functional ischemia study or ischemic symptoms AND an angiographic minimal 
lumen diameter stenosis ≥50% by [CONTACT_13775], or revascularization of a target vessel with diameter 
stenosis ≥70% by [CONTACT_592526] a positive functional study.  
4.2.9 Acute Success Rates 
Device success  is defined as the attainment of <50% final residual stenosis of the target lesion 
using only the NIRxcell Stent System. 
Lesion success  is defined as the attainment of <50% fi nal residual stenosis of the target lesion 
using any percutaneous method. 
Procedure success  is defined as attainment of <50% residual stenosis of the target lesion and 
no in-hospi[INVESTIGATOR_39473], MI or TLR. 
Medinol Confidential 
[ADDRESS_781470]-Market Study Protocol # CV103-[ADDRESS_781471]-Market Study Protocol # CV103-[ADDRESS_781472]–index stenting procedure. An 
unscheduled follow up may be conducted as clinically warranted. 
5.1 Control of Systematic Error/Bias 
By [CONTACT_592527], blinding of the investigator and/or subject is 
not possible.  However, several measures will be implemented for minimization of systematic 
error/bias: 
 Basic screening will be completed by [CONTACT_592528]. 
Subjects who fail to meet the clinical  inclusion and exclusion criteria will not be included 
in this study. Subjects who have met all the clinical inclusion and exclusion criteria will 
then be screened for angiographic eligibility criteria. 
 All subjects who undergo angiographic screening will be entered onto the screening log. 
The screening log will include all subjects who have signed the informed consent.  
 Measurements made by [CONTACT_592529]. The core laboratory measurements  will be used in all cases for purposes of 
data analysis.  
In determining subject eligibility for the study, the investigator’s assessment of pre-
procedure angiographic parameters will be used. However, the angiographic core 
laboratory will provide feedba ck to the sponsor concerning  accuracy of assessments in 
relation to inclusion criteria such as lesion parameters and anatomic location. 
 Electrocardiogram (ECG) tracings analysis will be standardized by [CONTACT_592530]. The ECG core laboratory readings will  be used in all cases for purposes of data 
analysis.   
 Clinical monitors will verify subjects’ data  and ensure compliance  with Good Clinical 
Practice (GCP), clinical protocol and other study requirements, according to the guidelines set forth in HCRI’s monitoring standard operating procedures (SOP). 
 An independent clinical events committee (CEC) will adjudicate all clinical endpoint 
events and investigator-reported adverse events  that have the poten tial to be a clinical 
endpoint event. The CEC adjudication results will be used in all cases for purposes of data 
analysis.  
5.[ADDRESS_781473]-Market Study Protocol # CV103-[ADDRESS_781474]’s body, the subject is considered to be 
enrolled. Subjects who do not meet all inclusion (general and angiographic) criteria or meet 
any of the exclusion criteria should not be enroll ed in the study. All subjects enrolled will be 
evaluated, regardless of sequence of treatment that ensues. 
Once a subject has been enrolled in the study, he/she may withdraw his/her consent to 
participate in the study at any time without prejudice. Participation in this clinical investigation is entirely voluntary.   
Possible reasons for subject discontinuation include but are not limited to the following:  
 Subject death  
 Subject voluntary withdrawal  
 Subject withdrawal by [CONTACT_26139]-indicated  
 Subject lost-to follow-up as described below  
Subjects withdrawn after treatment will not be required to undergo follow-up after 
withdrawal; however, they will still be considered part of the subject cohort.   
All subjects enrolled in the study are considered eligible for follow-up and will be required to 
adhere to the follow-up schedule outlined in Sect ion  9. If a subject cannot be contact[CONTACT_5365] a 
follow-up assessment and follow-up information cannot be obtained, he/she will be counted as “missed contact” for that specific schedule. Attempts shall be made to contact [CONTACT_592531]-up schedule. A subject will be cons idered “lost to follow-up” only after the last 
scheduled follow-up assessment for that subject (3 years). If a subject is lost to follow-up, the 
methods used to attempt to contact [CONTACT_592532]. At least [ADDRESS_781475]-Market Study Protocol # CV103-02 Page 22 of 72 
Version 1.2 Figure 1: Study Flowchart 
  
 
Yes
Identify Potential Subjects
Does subject have coronary 
artery disease and qualify for 
coronary artery 
revascularization? 
Follow-up Visits
 Hospi[INVESTIGATOR_2345] 
 1 month (± 14 days) 
 9 months (± 30 days) 
 1 year (± 30 days) 
 2 years (± 30 days) 
 3 years (± 30 days) Yes
Pre-Procedure Testing
Does subject qualify based on pre-procedure 
tests performed according to investigational 
site’s standard of care?
Index Procedure
Does subject satisfy angiographic eligibility 
criteria based on baseline coronary 
angiography? 
Subject is a screen 
failure No
Informed Consent
Did subject provide written informed 
consent? 
Subject is not a 
study candidateNo
Subject is a 
screen failure No
Yes
Subject is a 
screen failure 
No
 Repeat any screening tests (e.g., ECG or labs) 
according to protocol requirements, if necessary.  
Are all test results acceptable?  
Subject is a screen 
failure 
YesNo
Yes
Index Procedure
Was the NIRxcell™ Stent System introduced into 
patient’s vasculature?
Subject is a 
procedure failureNo
Yes
Enrollment
Subject is considered enrolled. 
Index Procedure
Treatment of target lesion with the NIRxcell™ 
Stent System
Medinol Confidential 
[ADDRESS_781476]-Market Study Protocol # CV103-[ADDRESS_781477] meet ALL  of the following criteria: 
6.1.[ADDRESS_781478] is ≥[ADDRESS_781479] is eligible for percutaneo us coronary intervention (PCI). 
3. Subject is eligible for dual anti-platelet therapy (DAPT) with aspi[INVESTIGATOR_592498], prasugrel or ticagrelor for a minimum of [ADDRESS_781480] is an acceptable candidate for coro nary artery by[CONTACT_9292] (CABG) surgery. 
7. Subject has stable angina pectoris (Canadian Cardiovascular Society Classification 
[CCSC] 1, 2, 3 or 4) or unstable angina pectoris (Braunwald Class 1-3, B-C) or a positive functional ischemia study (e.g., exercise tolerance test [ETT], single-photon 
emission computerized tomography [SPECT ], stress echocardiography or cardiac 
computerized tomography [CT]). 
8. Female subjects of child bearing potential must have a negative pregnancy test within 
[ADDRESS_781481] is indicated for elective stenting of a single stenotic lesion in a native 
coronary artery. 
2. Reference vessel 
≥2.5 mm and ≤4.0 mm in diameter by [CONTACT_13729]. 
3. Target lesion ≤30 mm in length by [CONTACT_13729] (the intention should be to cover 
the whole lesion with 1 stent of adequate length). 
4. Target lesion stenosis ≥50% and <100% by [CONTACT_13729]. 
6.[ADDRESS_781482] be excluded from this study if ANY  of the following criteria is met: 
6.2.[ADDRESS_781483] was enrolled in another stent trial w ithin 2 years prior to the index procedure. 
3. Any planned elective surgery or percutaneous intervention within nine (9) months 
post- procedure. 
Medinol Confidential 
[ADDRESS_781484]-Market Study Protocol # CV103-[ADDRESS_781485]-procedure. 
6. The target lesion requires treatment with a device other than percutaneous 
transluminal coronary angioplasty (PTCA) prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, 
etc.). 
7. Previous drug-eluting stent (DES) deployment anywhere in the target vessel. 
8. Any previous DES deployment within the past 12 months.  
9. Any previous stent placement within 15 mm proximal or distal to the target lesion. 
10. Co-morbid condition(s) that could limit the s ubject’s ability to participate in the trial 
or to comply with follow-up requirements, or  impact the scientific integrity of the 
trial.  
11. Concurrent medical condition with a life expectancy of <3 years. 
12. Documented left ventricular ejection fraction (LVEF) <25% at the most recent 
evaluation. 
13. Evidence of an acute MI within 72 hours of the intended index procedure. 
14. History of cerebrovascular accident or transi ent ischemic attack within 6 months prior 
to the index procedure. 
15. Leukopenia (leukocytes <3.5  10
9/liter). 
16. Neutropenia (absolute neutrophil count <1,000/mm3) ≤ within 7 days prior to 
enrollment. 
17. Thrombocytopenia (platelets <1,00,000/mm3) (within 7 days prior to enrollment). 
18. Active peptic ulcer or active gastrointestinal (GI) bleeding. 
19. Subjects who are ineligible for ≥[ADDRESS_781486] 
media that cannot be adequately pre-medicated. 
21.  Serum creatinine level >2.5 mg/dL within  [ADDRESS_781487]-Market 
Study. 
6.2.2 Angiographic Exclusion Criteria  
1. Unprotected left main coronary artery disease (obstruction >50% in the left main 
coronary artery that is not protected by ≥1 non-obstructed by[CONTACT_592533] (LAD) or left circum flex (LCX) artery or a branch thereof. 
Medinol Confidential 
[ADDRESS_781488]-Market Study Protocol # CV103-02 Page 25 of 72 
Version 1.2 2. Target vessel exhibiting multiple lesions with >60% diameter stenosis outside of a 
range of 5 mm proximal and distal to the target lesion based on visual estimate or on-
line quantitative coronary angiography (QCA). 
3. Target lesion exhibiting an intraluminal thrombus (occupying >50% of the true lumen 
diameter) at any time prior to the start of the intervention. 
4. Lesion location that is aorto-ostial or within 5 mm of the origin of the LAD or LCX. 
5. Target lesion with side branches >2.0 mm in diameter. 
6. Target lesion involving a bifurcation (either stenosis of both main vessel and major 
branch or stenosis of just major branch). 
7. Target lesion with severe calcification. 
8. Target vessel exhibiting excessive tortuosity that may impede stent delivery and 
deployment at target lesion. 
9. Target lesion that is located in a native vessel distal to an anastomosis with a 
saphenous vein graft or a le ft/right internal mammary artery (LIMA/RIMA) by[CONTACT_6476]. 
Medinol Confidential 
[ADDRESS_781489]-Market Study Protocol # CV103-02 Page 26 of 72 
Version 1.2 7 Treatment Methodology 
Table 2: Summary of Study Procedures from Screening through End of Follow-Up  
Study 
Requirement  Screening 
Procedure Post-Procedure 
 
Within 7 
Days  Prior to 
Procedure 
24 Hours 
Prior to 
Procedure
Hospi[INVESTIGATOR_138007] 
30 Days  
(±2 Weeks) 
9 Months 
 (±1 Month) 
1 Year 
 (±1 Month) 
2 Years 
 (±1 Month) 
3 Years 
 (±1 Month) 
Unscheduled 
Visit /Phone 
Informed 
consent X          
Medical history X          
Clinical 
assessment and 
physical exam X   X      X (7) 
Telephone 
assessment     X X X  X X X 
CBC 
w/differential (1) X          
Serum 
creatinine X          
INR, APTT X         X (7) 
Pregnancy test X (2)          
CK/CK-MB/ 
troponin  X (3)  X (6)      X (7) 
12-lead ECG  X (4)        X (7) 
Record of 
relevant 
medications (5)  X  X X X X X X X 
Coronary 
angiography   X        
Stenting   X        
Record of 
adverse events   X X X X X X X X 
APTT: activated partial thromboplastin time; CBC: complete blood count; CK: creatinine kinase; CK-MB: creatinine kinase 
myocardial band; ECG: el ectrocardiogram; INR: international normalized ratio 
(1) Collection of CBC differentials during the index hos pi[INVESTIGATOR_592499].  However, if the white  blood count (WBC) is abnormal, it is recommended to 
perform the CBC differential before and after the procedure. 
(2) For females of childbearing potential. 
(3) Pre-procedure cardiac enzymes: CK , CK-MB or troponin performed within  [ADDRESS_781490] and the time of arterial access.  
(4) Pre-procedure 12-lead ECG: an ECG performed within [ADDRESS_781491] been no signs or sy mptoms of myocardial ischemia between the time of 
ECG and the time of arterial access.   
(5) Relevant medications: statins, angiotensin converting enzyme inhibitors (ACE-I), angiotensin receptor 
blockers (ARB), beta-blockers and anti-platelets. 
Medinol Confidential 
[ADDRESS_781492]-Market Study Protocol # CV103-02 Page 27 of 72 
Version 1.2 (6) CK and CK-MB will be measured at 6- [ADDRESS_781493] procedure (or upon discharge, whichever comes firs t). If any CK elevation (CK above ULN) is noted 
post procedure, CK and CK-MB measurements will continue to be performed every [ADDRESS_781494] elevation is noted and reco rded on the appropriate eCRF. If total CK values are 
within normal ranges, CK-MB measurements may not be performed (per hospi[INVESTIGATOR_137288]). However, it is 
strongly encouraged that CK-MB measurements are obtaine d with every total CK drawn, even if CK values 
are within normal limits. It is also recommended that sites collect CK and CK-MB preferentially over 
troponin in the peri-procedural period subsequent to the index procedure.  In the case where CK and CK-MB 
are not available, troponin can be used. 
(7) These assessments and tests will be perf ormed only if clinically warranted. 
 
7.[ADDRESS_781495] Screening/Assessment 
Signed written informed consent must be obtaine d for all subjects who are potential study 
candidates prior to enrollment. Additionally, th e following evaluations must be completed for 
all subjects unless otherwise specified:   
Within 7 Days of Enrollment: 
 Medical history. 
 Clinical assessment and physical examination. 
 Complete blood count (CBC) with differential (if possible as per the respective 
institutions standard of care). 
 Chemistry screen including serum creatinine.  
 Coagulation including international normalized ratio (INR), activated partial 
thromboplastin time (APTT). Note: must be checked prior to heparin therapy. 
 Pregnancy test (for females of childbearing potential). 
Within 24 hours of Enrollment: 
 CK, CK-MB or troponin levels. 
 12-lead ECG (an ECG performed within [ADDRESS_781496] been no signs or symptoms of myocardial 
ischemia between the time of ECG and the time of arterial access). A copy of the ECG trace should be sent to the ECG core laboratory. 
 Record of relevant medications. 
7.2 Procedural Information 
For information describing the procedural steps and materials necessary for appropriate use of 
the NIRxcell Stent System, refer to the US Instructions for Use. 
Additionally, note the following: 
 Start of the Procedure and Enrollment 
The start of the procedure is defined as the time of arterial cannulation. Actual enrollment 
in the study occurs at the time the study device is introduced into the body. If the angiogram performed at the index procedure indicates that the subject is not a candidate 
for the study, this subject is not considered enrolled. 
Medinol Confidential 
[ADDRESS_781497]-Market Study Protocol # CV103-02 Page 28 of 72 
Version 1.2  Angiographic Protocol Requirement 
o Following intracoronary injection of 50–200 g nitroglycerin (NTG), obtain 
baseline angiograms using at least ≥[ADDRESS_781498] demonstrating the 
coronary artery stenosis, as specified in the angiographic protocol. 
o Before stent placement, obtain a single working view of the coronary artery stenosis, 
as specified in the angiographic protocol. 
 Pre-Dilatation 
If the target lesion fulfills eligibility criteria, the target lesion must be pre-treated with 
standard percutaneous transluminal balloon angioplasty. This clinical protocol does not allow for direct stenting of the target vessel.  
Attention must be paid to the pre-dilatation  technique to avoid balloon injury to any 
segment of the vessel that will not be entirely covered by [CONTACT_13732] (‘geographical miss’).  
Pre-dilatation must be performed using a balloon with the following 3 characteristics:  
1. A diameter 
≥0.5 mm smaller than the treatment stent. 
2. A length matching or shorter than the lesion length to be dilated (to avoid dilatation of 
the vessel wall adjacent to the stent). 
3. A length shorter than the stent to be implanted. 
The use of other therapy (e.g. cutting balloons, atherectomy, laser, thrombectomy, etc.) is 
not allowed.  
 Selection of Appropriately Sized Stent 
Select an appropriately sized stent based on angiographic vessel measurements 
(approximately 2–4 mm longer than the measured shoulder-to-shoulder lesion length, with 
a stent to distal reference vessel ratio of 1:1 or 1.1:1.0). The intention should be to cover 
the whole lesion with 1 stent of adequate length.  
Note : Additional NIRxcell Stent Systems should be  used, at the physician’s discretion, for 
sub-optimal result, or in the event of bailout procedures, as defined below. 
 Bailout Procedures 
The intention should be to cover the index lesion with [ADDRESS_781499] enrolled in the study experiences a major dissection 
or an occlusive complication (as evidenced by [CONTACT_13734], chest pain, or ischemic ECG changes that do not respo nd to repeat balloon inflations, NTG, 
intracoronary verapamil, intracoronary diltiaze m, or lytic agents), bailout procedures may 
be performed. For bailout procedures or in the event of a sub-optimal result, further stenting may be employed, at investigator’s discretion, using the NIRxcell Stent Systems, 
as required.  
 End of the Procedure 
The end of the procedure is defined as the time that the final guiding catheter is withdrawn 
from the subject. Closure of the arterial puncture site will be performed as per laboratory 
Medinol Confidential 
[ADDRESS_781500]-Market Study Protocol # CV103-02 Page 29 of 72 
Version 1.2 standards. The hemostasis introducer sheath(s) may be removed when the subject's 
activated clotting time (ACT) is <150 seconds or per the physician’s discretion. If a guide 
catheter is introduced once the procedure is considered over, as defined above, or the 
subject is returned to the procedure room an d interventional therapy is performed, this 
should be considered a repeat intervention.   
 Adverse Events Recording 
All adverse events (AEs) occurring following informed consent signature [CONTACT_592556].   
Note : Bailout procedures performed during the same catheterization as the index stenting 
procedure shall be considered part of the index procedure. 
7.[ADDRESS_781501]-Procedure Assessment (Hospi[INVESTIGATOR_3849]) 
Clinical assessment of a subject’s condition must be performed according to the details below.  
The research coordinator will review the follow-up requirements with the subject to help ensure compliance with the follow-up schedule. Telephone numbers must be obtained from 
the subject to ensure the ability to contact [CONTACT_58253] m/her. These phone numbers should include all 
home numbers, work numbers and primary physician numbers. A phone number of a relative or friend should also be requested. 
 
The following assessments will be pe rformed at hospi[INVESTIGATOR_2345]: 
 Clinical assessment and physical examination. 
 CK and CK-MB will be measured at 6- [ADDRESS_781502] procedure (or upon discharge, whichever comes first). 
If any CK elevation (CK above ULN) is noted post procedure, CK and CK-MB measurements will continue to be performed every [ADDRESS_781503] ed on the appropriate eCRF. If total CK 
values are within normal ranges, CK-MB measurements may not be performed (per hospi[INVESTIGATOR_137288]). However, it is strongly encouraged that CK-MB measurements are 
obtained with every total CK dr awn, even if CK values are within normal limits. It is 
also recommended that sites collect CK and CK-MB preferentially over troponin in the peri-procedural period subsequent to the index procedure. In the case where CK and 
CK-MB are not available, troponin can be used.Record of relevant medications (statins, 
angiotensin converting enzyme inhibitors [ACE-I], angiotensin receptor blockers [ARB], beta-blockers and anti-platelets). 
 Record of all AEs that occurred since the end of the index procedure. 
Medinol Confidential 
[ADDRESS_781504]-Market Study Protocol # CV103-02 Page 30 of 72 
Version 1.2 8 Concomitant Medications 
Concomitant medications to be used before, during and after the stenting procedure are as 
follows: 
Table 3: Summary of Concomitant Medications Regimen  
 Pre-Procedure Procedure Post-Procedure 
Aspi[INVESTIGATOR_248] A minimum of 150 mg 
(within 24 hours prior to procedure). --- 75–100 mg daily 
indefinitely. 
Clopi[INVESTIGATOR_592500]/ 
Ticagrelor Loading dose of [ADDRESS_781505]-procedure (within 30 
minutes). 
Alternatively, loading 
dose of [ADDRESS_781506]-procedure 
treatment with the same thienopyridine 
agent for a minimum of 1 month as follows:  
Clopi[INVESTIGATOR_7745]: 75 mg 
daily. 
Prasugrel: 10 mg daily; 
a lower dose of 5 mg daily is allowed for 
subjects <60 kg.  
Ticagrelor: 90 mg twice daily. 
Heparin or  
Bivalirudin --- Per routine hospi[INVESTIGATOR_8385].   
For heparin, a bolus of 50–
80 units/kg is recommended.  If heparin is administered, it 
is recommended to maintain 
ACT of ≥250 seconds (or 
≥200 seconds if a 
glycoprotein IIb/IIIa receptor blocker is 
administered) throughout 
the interventional portion of the procedure. --- 
Glycoprotein 
IIb/IIIa 
Inhibitor --- Per investigator’s 
discretion.  
Intracoronary 
Nitroglycerin  
or Intracoronary 
Isosorbide 
or Dinitrate --- To eliminate coronary 
artery spasm that would 
interfere with accurate measurement of lumen 
obstruction due to plaque 
alone, 100–200 µg nitroglycerin or 1–[ADDRESS_781507]-Market Study Protocol # CV103-[ADDRESS_781508]-procedure via 
telephone call. Refer to the text below for details. 
Additional unscheduled follow up visits/phone calls may occur as clinically warranted.  
The window for the 30-day follow-up contact [INVESTIGATOR_1317] ±2 weeks. For the 1-, 2- and 3-year 
contacts, the window will be ±1 month.  
9.1 30-Day ( ±2 Weeks) Contact 
 Record of relevant medications.  
 Record of all AEs that occurred since last subject contact. 
9.2 9-Month ( ±1 Month) Contact 
 Record of relevant medications.  
 Record of all AEs that occurred since last subject contact. 
9.3 1-Year ( ±1 Month) Contact 
 Record of relevant medications.  
 Record of all AEs that occurred since last subject contact. 
9.4 2-Year ( ±1 Month) Contact 
 Record of relevant medications.  
 Record of all AEs that occurred since last subject contact. 
9.5 3-Years ( ±1 Month) Contact 
 Record of relevant medications. 
 Record of all AEs that occurred since last subject contact. 
9.6 Unscheduled visit/Phone follow up 
 Record of relevant medications.  
 Record of all AEs that occurred since last subject contact. 
 Additional assessments and tests may be performed if clinically warranted. 
During each specified evaluation, the corresponding electronic case report form (eCRF) must 
be completed per the written instructions provided by [CONTACT_456]. Although not anticipated, should the appropriate authorized regulatory bodies request additional follow-up, the 
physicians and subjects will be requ ested to adhere accordingly.  
Detailed Explanations 
Adverse Events : 
Adverse events occurring (1) from time of index procedure to [ADDRESS_781509], (2) From [ADDRESS_781510], (3) From [ADDRESS_781511], and (4) From [ADDRESS_781512]-Market Study Protocol # CV103-02 Page 32 of 72 
Version 1.2 angiography/revascularization, the event related coronary angiograms and catheterization 
report must be captured and submitted to the data center within [ADDRESS_781513] be made available to the CEC for an independent review and assessment. Likewise, the angiographic images should be submitted to the core laboratory for an 
independent review and assessment of the target lesion and study stent.  
12-Lead ECG : According to each site’s standard of care.  
CBC With Differential : Hematology testing due to anti-pla telet therapy should follow the 
routine standard of care. 
CK, CK-MB and Troponin : CK, CK-MB or troponin will be obtained pre-procedure (within 
24 hours of the index procedure). Post proce dure, CK and CK-MB will be measured at 6- [ADDRESS_781514] procedure (or upon discharge, whichever comes first). If any CK elevation (CK above ULN)  is noted post procedure, CK and CK-MB 
measurements will continue to be performed every [ADDRESS_781515] elevation is noted and recorded on the ap propriate eCRF. If total CK values are within 
normal ranges, CK-MB measurements may not be performed (per hospi[INVESTIGATOR_137288]). However, it is strongly encouraged that CK-M B measurements are obtained with every total 
CK drawn, even if CK values are within normal limits. It is also recommended that sites 
collect CK and CK-MB preferentially over troponin  in the peri-procedural period subsequent 
to the index procedure.  In the case where CK and CK-MB are not available, troponin can be 
used. 
Relevant Medications : Statins, ACE-I, ARB, beta -blockers and anti-platelets. 
Medinol Confidential 
[ADDRESS_781516]-Market Study Protocol # CV103-02 Page 33 of 72 
Version 1.2 10 Total Expected Duration of the Clinical Investigation 
 The clinical investigation is estimated to commence in June 2015.  
 The enrollment is estimated to commence in July 2015. 
 Enrollment completion is estimated for October 2016. 
 The last patient follow up at 3 years is estimated for October 2019. 
 Total expected duration of the clinical investigation is approximately 4-[ADDRESS_781517]-Market Study Protocol # CV103-02 Page 34 of 72 
Version 1.2 11 Adverse Events 
In this study, subjects should be encouraged to report adverse events (AEs) spontaneously or 
in response to general, non-directed questioning (e.g. “How has your health been since the last 
contact?”). Any time during the study, the subj ect may volunteer information that resembles 
an AE. If it is determined that an AE has occurred, the Investigator should obtain all the information required to complete the AE eCRF. 
11.[ADDRESS_781518] clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the study device. 
NOTE 1:  This definition includes events related to the study device or the comparator. 
NOTE 2:  This definition includes events related to the procedures involved. 
NOTE 3:  For users or other persons, this definition  is restricted to events related to the 
study device. 
In this study, AEs shall be assessed and documented  at IC signing. All AEs are to be recorded 
through the end of the study on the appropriate subject case report forms and followed 
through to their resolution regardless of time window.    
11.1.[ADDRESS_781519] (ADE) is defined as an AE related to the use of the study device. 
NOTE 1:  This definition includes AEs result ing from insufficient or inadequate 
instructions for use, deployment, implantation, installation, or operation, or any malfunction of the study device. 
NOTE 2:  This definition includes any event resu lting from user error or from intentional 
misuse of the study device. 
11.1.3  Serious Adverse Event   
A Serious Adverse Event (SAE) is any AE that leads to: 
1. Death 
2. Serious injury that: 
a. Is a life-threatening illness or injury or 
b. Results in permanent impairment of a body function or permanent changes to a body 
structure or 
c. Necessitates medical or surgical interventi on to preclude permanent impairment of a 
body function or permanent damage to a body function. 
NOTE 1:  Planned hospi[INVESTIGATOR_5912]-existing condition, or a procedure required by 
[CONTACT_592534], and not meeting any of  the serious criteria described above, is not 
considered to be an SAE. A planned hospi[INVESTIGATOR_592501]. 
Medinol Confidential 
[ADDRESS_781520]-Market Study Protocol # CV103-[ADDRESS_781521] (SADE) is any anticipated ADE that has resulted in any of the 
consequences characteristic of an SAE. 
11.1.5  Anticipated Adverse Event 
Any undesirable experience (sign, symptom, il lness, abnormal laborato ry value, or other 
medical event) occurring to a subject, whether or not considered related to the study product(s) prescribed as part of the clinical protocol, predefined in the clinical protocol and/or 
Instructions for Use (IFU), product label that is  identified or worsens during a clinical study. 
11.1.[ADDRESS_781522] (UADE) is defined in 21 CFR 812.3(s) as any serious 
adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in 
nature, severity or degree of incidence in th e protocol, or any other unanticipated serious 
problem associated with a device that relates to  the rights, safety, or welfare of a subject.  
11.[ADDRESS_781523] to its identity, quality, durability, 
reliability, safety, or performance. Device deficiencies include malfunctions, user errors, and inadequate labeling, as detailed below:  
Device malfunction:   
Failure of an investigational medical device to perform in accordance with its intended 
purpose when used in accordance with the instructions for use or Clinical Investigational Plan 
(CIP) 
Malfunction per FDA CFR [§803.3(m)] means the failure of a device to meet its performance 
specifications or otherwise perform as intended. Performance specifications include all claims 
made in the labeling for the device. The intended performance of a device refers to the 
intended use for whic h the device is labeled or marketed. 
Use error: 
Act or omission of an act that results in a diffe rent medical device response than intended by 
[CONTACT_3460] 
• NOTE 1 - Use error includes slips, lapses, and mistakes. • NOTE [ADDRESS_781524]-Market Study Protocol # CV103-02 Page 36 of 72 
Version 1.2 Inadequate labeling: 
Label is not legible; label is torn; label is missing. 
11.[ADDRESS_781525] be listed on the appropriate eCRF. 
All AEs will be characterized by [CONTACT_4868]:  
 Intensity or Severity 
 Relatedness 
 Outcome 
 Treatment or Action Taken 
All AEs (serious and non-serious) will be reported for the entire study period in accordance 
with national laws.   
11.3.1  Intensity or Severity 
The following categories of the intensity of an AE are to be used:  
Mild:  Awareness of a sign or symptom that doe s not interfere with the subject’s usual 
activity or is transient, resolved w ithout treatment and with no sequelae; 
Moderate:  Interferes with the subject’s usual activity, but the subject is still able to 
function; 
Severe:  Events that interrupt a subject’s usual daily activity and generally require a 
systemic drug therapy or other treatment. 
11.3.2  Relatedness 
The Principal Investigator (PI) will evaluate if the AE or SAE is related to the investigational 
device or study procedure.  Relatedness is defined in the following manner: 
 UNRELATED: The event is clearly not related to the investigational trial 
device/procedures. 
 UNLIKELY RELATED: The event is unlikely to be related to the trial device/ 
procedure. 
 POSSIBLY RELATED: The event is possibly related to the trial device/procedure. 
 RELATED: The event is clearly relate d to the trial device/procedure. 
11.3.[ADDRESS_781526] observation will be characterized as 
follows: 
 Not Recovered/Not Resolved 
 Recovered/Resolved 
 Recovered/Resolved with Sequelae  
Medinol Confidential 
[ADDRESS_781527]-Market Study Protocol # CV103-02 Page 37 of 72 
Version 1.2  Recovering/Resolving 
 Fatal 
 Unknown 
11.[ADDRESS_781528] be submitted using the Study 
Exit eCRF along with a brief statement of the pertinent details, and the death 
records/certificate or autopsy report, if available/performed. 
It is the responsibility of each Investigator to report all SAEs to the reviewing IRB, according 
to national regulations and IRB requirements. A copy of the IRB report should be forwarded 
to the sponsor or its aut horized representative.  
Reportable events to be reported by [CONTACT_592535] r 21 CFR 803 Medical 
Device Reporting (MDR) 
“MDR reportable events” are events that the sponsor becomes aware of that reasonably 
suggest that one of their marketed devices may have caused or contributed to a death or 
serious injury, or has malfunctioned and the malfunction of the device or a similar device that 
they market would be likely to cause or co ntribute to a death or serious injury if the 
malfunction were to recur (21 CFR 803.3 and 803.50). 
Any event which meets both basic reporting criteria A and B listed below is considered a 
reportable event and must be reported to  the FDA. The criteria are as follows: 
A. An event has occurred that led, or might have led, to one of the following outcomes: 
a) Death, 
b) Serious injury that: 
 Is a life-threatening illness or injury or 
 Results in permanent impairment of a body function or permanent changes to a 
body structure or 
 Necessitates medical or surgical intervention to preclude permanent impairment 
of a body function or permanent damage to a body function   
B. The sponsor’s device is suspected to be a contributory cause of the event. 
This means that a death or serious injury was or may have been attributed to a medical device 
or that a medical device was or may have been a factor in a death or serious injury, including events occurring as a result of [21 CFR 803.3]: 
a) Failure 
b) Malfunction 
c) Improper or inadequate design 
Medinol Confidential 
[ADDRESS_781529]-Market Study Protocol # CV103-02 Page 38 of 72 
Version 1.2 d) Manufacture 
e) Labeling  
f) User error 
Additionally, it is the responsibility of the spons or to submit the following reports to the FDA: 
1. A “30-day initial report” must be submitted within 30 calendar days after the day the 
sponsor becomes aware of a reportable device-related death or serious injury, or a 
reportable malfunction. 
2. A “5-day report” must be submitted to the FDA within [ADDRESS_781530] reportable event:  
 That necessitates remedial action to prevent an unreasonable risk of substantial harm 
to public health or  
 For which the FDA have made a written request for the submission of 5-day reports. 
3. A “supplemental” or “follow-up report” must be submitted whenever the sponsor obtains 
information not known or available at the time of submission of the initial 30-day or 5-day 
report. 
11.4.[ADDRESS_781531] Reporting under 21 CFR 803 & [ADDRESS_781532] be documented by [CONTACT_592536], a complete description of the even t, possible reason(s) for the 
event, severity, duration, actions taken, and outcome. Copi[INVESTIGATOR_592502]. 
A report from the sponsor will be submitted to the FDA and to all reviewing IRBs and 
participating Investigators within [ADDRESS_781533]. The sponsor will submit other reports as required by [CONTACT_1622].  
11.4.3  Device Deficiencies  
All deficiencies and NIRxcell™ Stent System malfunctions will be documented on the 
appropriate eCRF and the malfunctioned device will  be returned to Medinol, if applicable, per 
written instructions, for analysis and be reporte d in the clinical results. Device deficiencies 
should be reported to Medinol and HCRI within  [ADDRESS_781534]-Market Study Protocol # CV103-02 Page 39 of 72 
Version 1.2 11.5 Reporting of Study Endpoint Adverse Events 
Whenever a clinical event related to a study endpoint is suspected or identified, all supporting 
source documents (i.e. progress notes, discharge summaries, catheterization lab reports, 
ECGs, lab results, etc.) should be submitted according to CEC source documentation 
collection procedures as soon as they are available. The source documentation required for each reported event is listed in the CEC charter.  
Medinol Confidential 
[ADDRESS_781535]-Market Study Protocol # CV103-[ADDRESS_781536]-procedure, in BMS patients.  To establish a TVF rate at 3 years following 
PCI with BMS, we performed a systematic search of the PubMed/MEDLINE literature database of articles published until November 25, 2011, with the follow ing search criteria: 
“Stents”[Mesh] AND coronary AND (“long te rm”[title] OR “long-term”[title] OR “3 
year”[title] OR “three year”[title]).  We supplemented this search strategy with a manual search of secondary sources, including references cited in the primary articles.  Subsequently, we limited the results to include only those stud ies with at least 3 years of follow-up and in 
which TVF was reported or could be calculated based on the outcomes reported. 
The primary search criteria yielded 86 headings.  After scanning the titles and abstracts of 
these headings, 8 full-text publications from 6 trials/programs were retrieved for additional 
analysis.  One additional report was retrieved th rough manual search.  Finally, the following 5 
trials/programs were identified as relevant accord ing to subject selection, type of intervention, 
and length of follow-up: TAXUS Clinical Program (I-IV),
[ADDRESS_781537] trials.26 
The studies identified employed diverse outcome criteria, and thus some adjustments for the 
reported data were made.  
1. Oculostenotic reflex : The current post-market study will evaluate subjects based on 
follow-up assessments performed by [CONTACT_756], and without mandatory angiographic 
assessment.  Hence, any repeat interventions will be performed solely based on 
clinical symptoms.  The observation that angiographic follow-up increases TLR and TVR rates when compared against clinical follow-up alone (the “oculostenotic reflex”) 
has been made previously with both balloon angioplasty and BMS.
5,27, 28  Thus, our 
expected TVR rate (as a component of TVF) will be lower than those observed in studies that utilized mandatory angiographic assessment.  To perform this adjustment, 
we analyzed [ADDRESS_781538] study, TAXUS IV,
27 
reported a TVR rate at 1 year of 18.9% in the angiographic cohort and 14.3% in the 
clinical cohort – a difference of 4.6%.  The second study, ENDEAVOR II,28 reported 
TVR rate at 8 months of 16.8% in the angiographic cohort and 8.2% in the clinical cohort – a difference of 8.6%.  We averaged these 2 studies to assume the difference in 
TVR rate between angiographically and clinically followed cohorts to be 6.6%.  We 
Medinol Confidential 
[ADDRESS_781539]-Market Study Protocol # CV103-[ADDRESS_781540] the rate of 1 year TVR according to the percentage of 
subjects undergoing repeat angiography in the trials included.  The number of non-
clinical TVR was then reduced from the overall TVR at 3–5 years. 
	݊݁ݒ݅ݎܦ	ݕ݈݈݈ܽܿ݅݊݅ܥሺܴܸܶ ௡ሻൌܴܸܶ ௡െ	0.066∙ܻ∙ܴܸܶ ଵ 
Where Y = percentage of subjects undergoing protocol driven angiography at 9–12 
months. 
2. Target vessel MI : Only 1 of the trials identified reported target-vessel MI rate 
(TAXUS).  The 5-year ratio of target vessel MI to all MI in this trial was 0.75.  We 
searched the medical literature for long-term re sults of clinical trials assessing BMS in 
similar subject populations, in which target-vessel MI was reported, but no additional 
data were found.  We identified 1 trial in which target-vessel MI was adjudicated after 
DES implantations.29  In this trial, the 2-year ratio of target vessel MI to all MI was 
0.9.  Thus, we assume that overall, the 3-year target-vessel MI is approximately 0.825 
of the overall rate of MI reported in the trials identified. 
3. Target vessel non-fatal MI : Only 1 of the trials identified  reported the fatality rate of 
MI.  In the RAVEL trial, the 3-year ratio of non-fatal MI to all MI was 0.75.  We used 
this proportion for the other stud ies included in our analysis. 
4. TVF : To match the TVF definition in the NIRTRAKS Post-Market Study, TVF was 
calculated as the sum of clinically driven TVR, target vessel non-fatal clinically 
relevant MI and cardiac death. 
5. TVF at 3 years : In the ENDEAVOR II trial, 50% of the combined long-term outcome 
of death, MI and TVR occurred in the first [ADDRESS_781541]-procedure.  For trials in 
which outcomes were reported for 4 or 5 years, we corrected the rates to 3 years by 
[CONTACT_105453] 50% of the events occurred during the first year, and the remainder were evenly distributed across the follow-up duration of years 2 to 5.  Thus, the 3-year event 
rate was calculated according to the following formula: 
ܨܸܶ
ଷൌ	ܨܸܶ ଵ൅ܨܸܶ௡
݊െ1 
Where 	ܨܸܶଵൌ0 . 5∙ܨܸܶ ௡ and n = number of follow-up years reported in original 
publication. 
We performed a random effects meta-analysis of the 3-year TVF rates from the BMS arms 
of included studies, following the approach in DerSimonian and Laird (1986).31 Based upon 
our analysis, the endpoint rate of TVF derived from the meta-analysis is 23.2% (95% CI 
19.8%, 26.7%). 
 
Medinol Confidential 
[ADDRESS_781542] Market Study Protocol # CV103-02 Page 42 of 72 
Version 1.2 Table 4: Subject and Lesion Characteristics in BMS Trials 
 
  Subject Characteristics Lesion Characteristics 
Trial No. of BMS 
Subjects Mean Age (y) Women (%) Diabetes 
Mellitus (%) RVD (mm) MLD (mm) Length 
(mm) 
TAXUS I-IV  1397 62.2 28.3% 25.6% 2.73 0.91 14.6 
RAVEL 118 59.7 32% 17.7% 2.[ADDRESS_781543]   25 61 24% 10% 2.71 Unknown 10.9 
ENDEAVOR II 599 63 24.5% 22.2% 2.76 0.84 14.38 
SIRIUS 525 62 30% 28% 2.[ADDRESS_781544] Market Study Protocol # CV103-02 Page 43 of 72 
Version 1.2 Table 5: Target Vessel Failure Rates in BMS Trials 
Trial No. of 
BMS 
Subjects Angio 
Follow-
Up 
N (%) TVR Clinically 
Driven TVR All MI Target 
Vessel MI Target 
Vessel 
Non-Fatal 
MI All 
Death Cardiac 
Death TVF   
TVF at 
3 Years 
 5-Year Data  
TAXUS I-IV  1397 1102 
(78.9%) -- 21.8%* 6.6% 5% 3.75% 9.1% 3.8% 29.35%  
22.01% 
SIRIUS 525 353 
(67.2%) 30.5% 29.5%** 6.5% 5.36% 4.02% 8.4% 3.6% 37.12%  
27.84% 
SPI[INVESTIGATOR_591981]   25 25 
(100%) -- 36% 0% 0% 0% -- 0% 36%  
27% 
 4-Year Data  
ENDEAVOR II 599 294 
(49.1%) -- 17.2%† 4.4% 
(non-fatal) 3.63% 
(non-fatal) 3.63% 5.2% 2.24%‡ 23.07%  
19.23% 
 3-Year Data  
RAVEL 118 118 
(100%) -- 17.7%§ 7.1% 5.86% 4.39% 4.4% 2.7% 24. 79%  
24.79% 
BMS: bare metal stent; MI: myocardial infarction; TVF: target vessel failure; TVR: target vessel revascularization. 
* We assumed a 5-year clinically driven TLR rate of 16.8% based on a 5-year TLR rate of 16.8% in 295 subjects with no routine a ngiographic follow-up.  In this 
trial the ratio of TVR to TLR at 5 years was 1.3.  We therefore assumed the clinically driven TVR rate to be 1.3 times the clin ically driven TLR rate.  
** Based on a 1-year TVR rate of 22.9%. 
† At 9 months, 26 events from the ENDEAVOR II cohort were reported as non-clinical (angio driven).  These were deducted from th e 129 events reported at 4 
years. 
‡ At 5 years, the proportion of cardiac deaths of all deaths was 0.42 in the TAXUS program and 0.43 in the SIRIUS trial.  We us ed this proportion (0.43) to 
calculate the rate of cardiac deaths at 4 years in the ENDEAVOR II trial. 
§ The sum of clinically driven TLR (15.0%) and all non-TLR TVR (2.7%).  
 
Medinol 
[ADDRESS_781545] Market Study Protocol # CV103-02 Page 44 of 72 
Version 1.2 12.2 Performance Goal 
The goal of the primary analysis will be to assess the comparability of the observed primary 
endpoint rate for the study stent to the meta-analysis derived rate (23.2%).  Based upon the 
meta-analysis, the expectation for the true primary endpoint rate for the study stent is equal to 
23.2%.  However, since strict equality cannot be assessed statistically, this non-randomized, single-arm study will assess if the study stent 3-ye ar TVF rate falls significantly below 34.8%.  
Specifically, this study will assess the ability of the study stent to meet a performance goal of 
34.8%, which is a 50% increase over the expected rate of 23.2% obtained from the meta-
analysis.  
12.[ADDRESS_781546] a primary endpoint rate 
greater than or equal to 34.8%.  The alternative hypothesis states that the NIRxcell will have a 
primary endpoint rate less than 34.8%.  
Specifically:   
H
o:  NIRTRAKS  ≥ 34.8% 
HA:  NIRTRAKS  < 34.8% 
where  NIRTRAKS  is the true primary endpoint rate fo r the study stent and the 34.8% is the 
meta-analytically derived performance goal (PG) for the primary endpoint rate.  Rejection of 
the null hypothesis will signify that the performance goal has been met, and that the study stent’s primary endpoint rate is less than 34.8%. 
The primary hypothesis test will be carried out by [CONTACT_592537] 1-
sided 95% confidence interval of the 3-year TVF ra te to 34.8%, the PG.  If this upper bound is 
less than 34.8%, then it will be considered th at the study stent meets the performance goal.  
The necessary sample size for testing the primary hypothesis was estimated with PASS 
software using exact hypothesis testing based on the exact distribution with the following 
assumptions: 
 Type I error ( α) = 0.05 (1-sided). 
 Statistical power (1 – β) = 83%. 
 PG = 34.8%. 
 
 NIRTRAKS  = 23.2%. 
An evaluable sample size of 105 provides 83% power to reject the above null hypothesis in 
favor of the alternative. Thus, 131 subjects will be enrolled to a ccount for loss to follow-up, 
which is expected to be approximately 7.0% per year. 
The loss to follow-up in previously published sten t trials with long-term follow-up is low.  In 
the SIRIUS25 trial, complete data compliance for a ll 5-year follow-up end points was 93.6% 
and 94% in the intervention and control groups, respectively.  At 9 months the clinical 
compliance was 100%32 in both groups.  In the ENDEAVOR II trial,23 out of 1,197 enrolled 
subjects, 1,167 were followed for 4 years (97.4%).  In the RAVEL trial24, complete data sets 
were available for 94.2% of subjects randomly assigned to sirolimus-eluting stents and for 



Medinol 
[ADDRESS_781547] Market Study Protocol # CV103-02 Page 45 of 72 
Version 1.2 94.1% of subjects randomized to BMS.  In the TAXUS IV trial,22 out of 1,314 intention-to-
treat (ITT) subjects, 5-year data were available for 1,294 (98.4%) subjects. In view of these 
data, we believe a yearly 7% loss-to-follow-up estimate is conservative and encompasses wide 
margins of safety. 
12.[ADDRESS_781548] 
analyzed regardless of the actual treatment received.   
12.4.2  Per-Protocol 
Per-protocol (PP) analysis will also be conducted. Per-protocol is defined as all subjects who 
sufficiently comply with the study protocol . Compliance covers treatment received, 
availability of follow-up data (f ollow-up of at least 3 years, allowing for a visit window of 3 
years ± 1 month), and absence of major protocol deviations.   
12.5 Endpoint Analyses and Reporting of Results 
Descriptive statistics will be used to present th e data and to summarize the results. Categorical 
variables will be presented using counts and percentages. Proportions will be calculated using 
known non-missing values. Continuous variables will be summarized by [CONTACT_592538] (N), mean, 2-sided 95% confidence interval of the mean, standard deviation, median, minimum and maximum values. Unless otherwise indicated, all statistical 
tests and/or confidence intervals will be performed at α = 0.05 (2-sided). 
For adverse event reporting, which includes the primary and secondary safety endpoints, the 
primary analysis will be based on subject coun ts, not event counts. A su bject with more than 
one event will be counted only once toward the event rate based on the total number of 
subjects with adverse events. Additionally, an event rate based on even t counts will also be 
presented. Unless specified otherw ise, statistical significance will be declared if the two-sided 
p-value is < 0.05. 
All statistical analyses will be performed us ing Statistical Analysis System (SAS) for 
Windows (version 9.1 or higher, SAS Institute  Inc. Cary, NC) or other widely accepted 
statistical or graphical software. In general, data for all study subjects will be combined and 
presented. Individual data will be presented in subject listings. 
12.[ADDRESS_781549] Market Study Protocol # CV103-02 Page 46 of 72 
Version 1.2 12.7 Analysis of Primary Endpoint 
An assessment of the null and alternative hypotheses from Section  12.3,  
Ho:  NIRTRAKS  ≥ 34.8% 
HA:  NIRTRAKS  < 34.8% 
will be carried out using the exact test of the bino mial distribution at the 1-sided 0.05 level of 
significance on ITT subjects who experienced the primary endpoint or who had follow-up 
within 1 month (the allowable window for the 3-year contact) of 3-years post-procedure.  If 
this upper interval is below 34.8%, the null hypo thesis above will be rejected in favor of the 
alternative (the results of the exact confidence interval approach will yield the same 
conclusion as the 1-sided exact test of the null hypothesis).  In addition, the assessment of the 
hypotheses will be carried out on all ITT subjects by (a) comparing the 1-sided upper 95% confidence interval of the Kaplan-Meier es timate of the primary endpoint rate to 34.8%; 
subjects not experiencing the endpoint will be censored at [ADDRESS_781550]-procedure or day of 
withdrawal, whichever is earlier; and (b) mu ltiply imputing the primary endpoint incidence 
for subjects prematurely withdrawing prior to [ADDRESS_781551] of hypothesis on the imputed data 
(see details in Section  12.8 below). The results of the various ITT analyses on the primary endpoint will be compared descriptively to assess the sensitivity of results to missing data. 
Finally, the analysis will be carried out on the PP population (secondary analysis) using the 
exact test of the binomial distribution and an exact 1-sided upper 95% confidence interval.  
12.8 Handling of Missing Data in the Analysis of the Primary Endpoint 
The primary analysis set will be the ITT populatio n, which includes all subjects enrolled into 
the study.  Subjects who prematurely withdraw prior to the 3-year (minus the allowable 1-month window) contact [CONTACT_592539] 3 approaches; results will be compared 
across the 3 approaches for consistency: 
1. Only subjects with appropriate follow up (at least 3 years minus 1 month) or who 
experienced the primary endpoint by [ADDRESS_781552] hypothesis 
testing, as discussed above.  This is the primary analysis.. 
2. Multiple imputation: This will be used to impute primary endpoint status (yes/no) for 
subjects with missing primary endpoint data.  The logistic regression approach to 
multiple imputation will be carried out using SAS PROC MI.  The covariates to be 
used in the imputation model will be age, sex, prevalence of diabetes, target lesion length and reference vessel diameter.  Five data sets will be imputed, and a 1-sided test 
of the above null hypothesis will be carr ied out on each data set using the normal 
approximation to the binomial distributio n.  SAS PROC MIANALYZE on the results 
of the [ADDRESS_781553] analysis and as discussed above, the Kaplan-Meier estimate of the 3-year 
primary endpoint rate, and its 1-sided upper 95% confidence interval will be calculated. Subjects not experiencing the primary endpoint within 3 years will be 

Medinol 
[ADDRESS_781554] Market Study Protocol # CV103-02 Page 47 of 72 
Version 1.2 censored at 3 years or the date of withdrawal from the study, whichever is earlier. The 
upper confidence limit will be compared to 34.8%; if less than 34.8%, the primary 
endpoint rate will be considered to be sign ificantly less than the performance goal in 
this analysis. 
12.9 Analysis of Secondary Endpoints 
All secondary endpoints (listed below) are dichotomous variables.  Secondary endpoints will 
not be tested formally.  Instead, secondary endpoints will be presented as the number and 
percentage of subjects experiencing the outcome, along with 2-sided exact 95% confidence 
intervals of the percentages.  In addition, a Kaplan-Meier (K-M) estimate of the event-free survival rate and its corresponding standard erro r will be presented for death, MI, clinically 
driven TLR and TVR, with a corresponding K-M curve. 
The secondary endpoints that will be reported are as follows: 
1. TVF  at 9 Months. 
2. All cause death  at 30 days, and 1, 2 and 3 years. 
3. Cardiac death  at 30 days, and 1, 2 and 3 years. 
4. All cause MI  at 30 days, and 1, 2 and 3 years. 
5. Target vessel MI  at 30 days, and 1, 2 and 3 years. 
6. Clinically driven TLR  at 30 days, and 1, 2 and 3 years. 
7. Clinically driven TVR  at 30 days, and 1, 2 and 3 years. 
8. Acute success rates  
Device success : Attainment of <50% final residual stenosis of the target lesion 
using the NIRxcell Stent System only. 
Lesion success : Attainment of <50% final residual stenosis of the target lesion 
using any percutaneous method. 
Procedure success : Attainment of <50% residual stenosis of the target lesion 
and no in-hospi[INVESTIGATOR_39473], MI or TLR. 
9. Stent thrombosis  at hospi[INVESTIGATOR_2345], at 30 days, and 1, 2 and 3 years. 
12.10  Pre-Planned Subgroup Analyses 
A subgroup analysis will be performed according to the following characteristics: ethnicity, 
race, gender, age group (less than and over 65), obesity (less than and over body mass index 
[BMI] of 30), diabetes mellitus, and site of ar terial access (trans-radial versus trans-femoral 
access).  The TVF rate with 95% CIs will be provided for each subgroup.  There will be no formal statistical analysis to compare TVR rates across these subgroups, as the study is not powered to detect such differences. 
12.[ADDRESS_781555] Market Study Protocol # CV103-02 Page 48 of 72 
Version 1.2 summary form, a comparison acr oss all sites on the primary endpoint will be completed via 
logistic regression to determine if the primary endpoint data can be pooled for the primary 
analysis.  A 0.15 level of significance will be us ed to assess site poolability.  A poolability P 
value < 0.15 will not necessarily preclude patients from being pooled across sites for the primary analysis.  Rather, further analysis will be  carried out to assess if it is appropriate to 
pool sites, such as (1) inspection of the primar y endpoint rate in each site to assess if the 
primary endpoint rate is at least descriptively less than the performance goal at each site; (2) a comparison of the following variables across sites to  assess if potential lack of site poolability 
on the primary endpoint may be due to differences in the following variables across sites: 
baseline demographics, procedural characteristics and protocol deviations.  
The distributions of the above variables across the sites will be tabulated.  To detect site 
differences, the Kruskal-Wallis test  will be used for continuous variables and the Chi-Square 
test or the Fisher’s exact test will be used for categorical variables, depending on sample size.
 
12.12  Clinical Events Committee 
The clinical events committee (CEC) will be comprised of both interventional and non-
interventional cardiologists who are not participants in the study and who have no conflict of interest with the study or the study sponsor.  All members of the CEC will be blinded to the 
primary results of the trial. 
The CEC will be responsible for the adjudication of clinical study endpoint events.  At the 
onset of the trial, the CEC will establish exp licit rules outlining the mi nimum amount of data 
required, and the algorithm followed in order to classify a clinical endpoint event.  The CEC 
will then meet regularly in approximately every [ADDRESS_781556] udy endpoint–related clinical events in which the required 
minimum data are available.  The committee will also review and rule on all deaths that occur 
throughout the trial.   
Once the specific criteria for clinical endpoin ts are established by [CONTACT_15741], HCRI will be 
responsible for categorizing all clinical endpoint events when all necessary data are available. 
  
Medinol 
[ADDRESS_781557] Market Study Protocol # CV103-[ADDRESS_781558] Keepi[INVESTIGATOR_007] 
13.1 Source Documents 
Source data is all information, original records of clinical findings, observations or other 
activities in a clinical study necessary for the reconstruction and evaluation of the study. 
Source data are contained in source documents.  Examples of these original documents and data records include but are not limited to: hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, subjects’ evaluation checklists, recording media such as DVD 
and video tapes, X-rays, subject files, and records kept at the laboratories and at other departments involved in the clinical trial.  
Source documents will be used: 
 For verification of the data documented in subjects’ eCRF during monitoring visits.  
 For adjudication of AEs.  Standardized forms will be designed to ensure proper collection 
of all requested source documentation from the sites.   
13.2 Electronic Case Report Form 
A web-based clinical data collection and presentation system will be used in this study.  The 
eCRF is the primary data collection instrument an d will be provided to the sites as a secured, 
private facility over the internet.  This system will include: 
 Complete eCRF-based data collection,  clarification and archival system. 
 Online query creation and resolution. 
 Electronic signatures compliant with 21 CFR Part 11. 
 Complete audit trail history. 
All data requested on the eCRF must be recorded.  All missing data must be explained: 
 If a space on the eCRF is left blank because the procedure was not done or the question 
was not asked, a comment must be created on the field to explain the blank field.  
 If the item is not applicable to the individua l case, a comment must be created on the field 
to explain the blank field.  
 If any entry error has been made, to correct such an error, the data must be edited 
including a reason for the correction and the eCRF re-submitted. 
Detailed description of the eCRF components as well as completion and handling instructions 
are provided in the eCRF Completion Guidelines.  
The eCRF must be fully completed for each su bject, electronically signed by [CONTACT_569852], and submitted to the data center.  eCRFs documenting SAEs, UADEs, device 
failures and device malfunctions should be submitted via the Electronic Data Capture (EDC) 
system as soon as possible, preferably within [ADDRESS_781559]’s enrollment or follow-up visit.  
Medinol 
[ADDRESS_781560] Market Study Protocol # CV103-02 Page 50 of 72 
Version 1.2 All angiographic and ECG media should be prepared and sent to the corresponding core 
laboratory, preferably within 7 working days of data collection.   
All collected study data will be made available (and sent in the appropriate format) to the 
sponsor, if requested, after the study has reached its primary endpoint at [ADDRESS_781561] further 
documentation such as physician and/or catheter laboratory procedure notes when SAEs are reported. 
Data entry and development of the primary database for the study will be managed by [CONTACT_592540].  The data center will also be responsi ble for the quality control of the database and 
confirming the overall integrity of the data. 
13.[ADDRESS_781562]-
Market Study administrative files at each inves tigational site.  These fi les should be retained 
for a minimum of 5 years after: the date on which the study is terminated or completed, OR 
the date on which there is no pending/contemplated action in any International Conference on Harmonisation (ICH) region, OR the date that the records are no longer required for purposes 
of supporting a marketing approval in ICH re gions, OR according to national regulatory 
requirements, whichever is later.  The files may be discarded only upon notification from the sponsor.  To avoid error, the principal investigator [INVESTIGATOR_592503]. 
The subject data for the study will be housed wi thin the database at the data center. At the 
completion of the study, the site will be sent a CD with the final subject data for the particular 
site. 
13.5 Study Device Accountability 
The Primary Investigator will maintain adequate records of the receipt and disposition of the 
NIRxcell on the device inventory log or case report form (CRF), including stent 
size/dimensions; date implanted; subject identi fication number; and implanting Investigator.  
 
  
Medinol 
[ADDRESS_781563] Market Study Protocol # CV103-[ADDRESS_781564] icable provisions of the sponsor’s monitoring 
procedures, in conformance with World Medical Association Declaration of Helsinki, and 
local regulations for post-approval clinical stud ies.  Additionally, applicable provisions of 
FDA regulation 21 CFR parts 812, 50 and 54 will be followed. 
Monitoring visits to the investigational sites will be made periodically during the study to 
ensure that: 
 The rights and well-being of study subjects are protected. 
 The reported study data are accurate, complete and verifiable from source documents. 
 The conduct of study is in compliance with approved protocol/amendment, with GCP, and 
with applicable regu latory requirements. 
A monitoring plan will be prepared a nd shall include information such as:  
 Parties (clinical research organization [CRO]/monitor and sponsor) and signatures. 
 Purpose. 
 Responsibilities. 
 Processes, such as: 
o Types of visits and expected scope of activities in each. 
o Level of source document verification and the key data to be monitored. 
o Communication paths and data flow to be followed. 
o Frequency of visits. 
o Reporting and documentation of monitoring activities. 
The principal investigator [INVESTIGATOR_592504], subject eCRFs and subject 
medical records, to staff of the sponsor and the sponsor’s study contractor(s) personnel, as well as regulatory authorities that govern the conduct of clinical investigations. 
The investigational sites may also be subject to a quality assurance audit by [CONTACT_592541]’s study contractor(s) personnel, as well as inspection by [CONTACT_592542]. 
It is important that the investigators and the relevant site personnel are available during the 
monitoring visits and possible audits and that sufficient time is devoted to the process. 
14.2 Training  
The training of clinical site personnel, as well as other personnel related to the study (i.e., CRO 
personnel) will be the responsibility of the sponsor.  To insure uniform data collection and protocol compliance, training will cover topi[INVESTIGATOR_592505], study protocol 
(with reference to applicable regulations), eCRF and completion instructions, and study 
processes and documentation (e.g., informed consent, safety handling and reporting, compliance handling and reporting).  All users of the EDC syst em will be trained in accordance to [ADDRESS_781565] Market Study Protocol # CV103-[ADDRESS_781566] the 
study according to the clinical protocol or the investigator agreement.  In this study protocol deviations will be classified as follows: 
Major deviation:  any deviation from subject inclusion and exclusion criteria or subject 
informed consent procedures. 
Minor deviation:  deviation from a clinical protocol requirement such as incomplete/inadequate 
subject tests or examinations, non-compliance with medication regimens, missed follow-ups, 
follow-ups performed outside specified time windows, etc.  
Investigators will not deviate from the protocol without the prior written approval of their IRB 
and the sponsor except when the change is necessary to eliminate apparent immediate hazards to 
the human subject or to protect the life or physical well-being of the subject or in unforeseen, isolated instances, where minor changes are made that will not increase the subject's risk or 
affect the validity of the study.   
Study sites should report all protocol deviations on the applicable eCRF.  Any deviation from the 
protocol made to protect the life or physical well-being of a subject in an emergency should be reported as soon as possible but no later than 5 working days after the emergency occurs.  
Investigators will also adhere to procedures for reporting protocol deviations to their IRB in 
accordance with their specific IRB reporting policies and procedures.  
14.4 Investigational Site Termination 
The sponsor reserves the right to terminate an investigational site for any of the following 
reasons: 
 Repeated failure to complete eCRFs. 
 Failure to obtain informed consent. 
 Failure to report SAE within 24 hours of knowledge 
 Repeated protocol violations. 
 Failure to enroll an adequate number of subjects. 
  
Medinol 
[ADDRESS_781567] Market Study Protocol # CV103-02 Page 53 of 72 
Version 1.2 15 Ethical and Regulatory Considerations 
15.1 Compliance Statement 
This trial will be conducted in accordance with this protocol, the Declaration of Helsinki and US 
Good Clinical Practice (21 CFR Part 50, 21 CF R Part 56, and 21 CFR Part 812), and the 
applicable regulatory requirements (such as 21 CFR Part 54, 21 CFR Part 11).  The conduct of the trial will be approved by [CONTACT_592543] (IRB) of the respective 
investigational site and the US Food and Drug Administration.  
15.[ADDRESS_781568] be 
approved in writing by [CONTACT_1201]; these changes will be considered as protocol amendments.  A 
significant change is one that may increase risk or present new risk to the subject, or may adversely affect the validity of the study.  Each investigator must receive approval for the 
amendment prior to implementing it at his/her investigational site.   
15.[ADDRESS_781569] in layman’s terms all aspects of the consent.  Informed consent must be obtained in 
accordance with ISO [ZIP_CODE]:2011, FDA regulation (21 CFR Part 50) and the Declaration of 
Helsinki and shall inform the subject as to the objective and procedures of the study and possible risks involved.  The subjects must be informed of their right to withdraw from the study at any 
time and for any reason without sanction, penalty or loss of benefits to which they are otherwise 
entitled, and that withdrawal from the study will  not jeopardize their future medical care.  
The NIRTRAKS Post-Market Study template informed consent form (ICF) that will be provided 
to the participating sites may be adjusted by [CONTACT_592544].  The NIRTRAKS Post-Market Study ICF must be used in addition to 
the institution standard consent form.  The IRB-approved study ICF must be sent to the sponsor for approval and a copy must be placed at the i nvestigational site in th e NIRTRAKS Post-Market 
Study binder.  The ICF form must be signed and dated by [CONTACT_29159]’s legally 
authorized representative, and the investigato r-designated research professional obtaining the 
consent.  A signed copy of the ICF must be given to each subject enrolled in the study.  
Modifications to the NIRTRAKS Post-Market Study ICF (e.g., additional safety or procedural 
information) and any written subject information throughout the study period, must be approved 
by [CONTACT_23638], as necessary, the IRB and other regulatory authorities as required by [CONTACT_592545] 
[ADDRESS_781570] Market Study Protocol # CV103-[ADDRESS_781571] re-consent is required.   
15.4 Confidentiality 
At all times throughout the study, confidentiality shall be observed by [CONTACT_5564].  All 
information and data sent to the data center, core laboratories and/or the sponsor concerning subjects or their participation in this study will be  considered confidential.  All data used in the 
analysis and reporting of this evaluation will be used in a manner without identifiable reference 
to the subject.  The principal investigator [INVESTIGATOR_592506]’s study contractor(s) personnel, as well as regulatory authorities that govern the conduct 
of clinical investigations.  
  
Medinol 
[ADDRESS_781572] Market Study Protocol # CV103-02 Page 55 of 72 
Version 1.2 16 Reporting Requirements 
16.1 Investigator Reporting Responsibilities 
Investigators are required to prepare and submit  the following data comp letely and accurately 
and within the time required: 
Table 6: Investigator’s Responsibilities  for Preparing and Submitting Reports 
Investigator reporting responsibilities 
Data Form Action Required Requirements 
Subject enrollment 
eCRF page Complete via EDC system Within [ADDRESS_781573] ECG Provide to ECG core laboratory Within 7 working days of exam 
SAE and UADE 
 
* Source documents 
should be sent to Monitoring CRO, upon request Complete via EDC system Within 24 hours of knowledge. 
Provide to IRB and FDA As required. 
AE Complete via EDC system If po ssibly or probably related to 
study device / procedure– complete eCRF within 24 hours 
of knowledge. Otherwise – complete within [ADDRESS_781574] withdrawal Complete via EDC system Within 7 working days of 
knowledge. 
Device deficiencies Complete via EDC system Within 24 hours of knowledge. 
Withdrawal of IRB 
approval Provide to Medinol either 
verbally or via email Within 5 working days of 
knowledge. 
Deviations from the 
clinical protocol   
 Failure to obtain 
informed consent prior to procedure Provide to Medinol (either 
verbally or via email) as well as 
to IRB and FDA. 
Also complete via EDC system Within [ADDRESS_781575] Market Study Protocol # CV103-02 Page 56 of 72 
Version 1.2 Investigator reporting responsibilities 
Data Form Action Required Requirements 
 Other deviation Complete via EDC system Within 7 working days of 
knowledge. 
Provide to IRB and FDA As required. 
Progress reports / 
notifications of site 
activity (e.g.: end of 
enrollment, end of study, etc.) Provide to IRB Annually for the duration of the 
clinical study. 
Final clinical summary 
report Provide to IRB, once available Re port must be submitted within 
3 months after termination or 
completion of the study. 
16.1.1  Investigator’s Final Report 
Upon completion or termination of the study a final report will be prepared.  This report will 
contain a critical evaluation of all data collected during the course of the study at each institution.  The report must be signed by [CONTACT_458] [INVESTIGATOR_592507].  Any modifications to this final report must be reviewed and approved by [CONTACT_103]. 
16.2 Sponsor Reporting Requirements 
The sponsor and HCRI will prepare written progre ss reports and a final report.  Medinol will 
submit the required reports as required by [CONTACT_446149] w.  This includes the following reports to the 
FDA according to 21 CFR 803: 
Table 7: Sponsor’s Responsibilities for Preparing and Submitting Reports 
What to Report Report Form To Whom When 
30 day reports of deaths, serious 
injuries and malfunctions Form FDA 
3500A FDA Within 30 calendar days of 
becoming aware of an event 
5-day reports for an event 
designated by [CONTACT_592546] 
3500A FDA Within 5 work days of 
becoming aware of an event 
18-month Progress Report* PAS Progress 
Report FDA 23 July 2015 
24-month Progress Report* PAS Progress 
Report FDA [ADDRESS_781576] Market Study Protocol # CV103-02 Page 57 of 72 
Version 1.2 What to Report Report Form To Whom When 
Progress Report* PAS Progress 
Report FDA Annually on January 23  
Final Report Final Study 
Report  FDA Anticipated - Dec 2019 
 
*PAS progress reports provided to FDA after star t of enrollment will be based on CEC adjudicated data.
Medinol 
[ADDRESS_781577] Market Study Protocol # CV103-02 Page 58 of 72 
Version 1.2 17 References 
1. Holmes DRJ, Vlietstra RE, Smith HC, Ve trovec GW, Kent KM, Cowley MJ, Faxon DP, 
Gruentzig AR, Kelsey SF, Detre KM, al. e. Restenosis after percutaneous transluminal coronary 
angioplasty (ptca): A report from the ptca registry of  the national heart, lung, and blood institute. 
Am J Cardiol . 1984;53:77C-81C 
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Sav age MP, Penn I, Detre K, Veltri L, Ricci D, 
Nobuyoshi M, al. e. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N 
Engl J Med . 1994;331:496-501 
3. Salam AM, Al Suwaidi J, Holmes DRJ. Drug-eluting coronary stents. Curr Probl Cardiol . 
2006;31:8-119 
4. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med . 2006;354:483-495 
5. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, Cohen DJ, Kuntz RE. 
Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll 
Cardiol . 2002;40:2082-2089 
6. Mauri L, O'Malley AJ, Cutlip DE, Ho KK, Popma JJ, Chauhan MS, Baim DS, Cohen DJ, Kuntz 
RE. Effects of stent length and lesion length on coronary restenosis. Am J Cardiol . 2004;93:1340-
1346, A1345 
7. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated 
with the use of paclitaxel-eluting stents for pe rcutaneous coronary intervention?: A meta-analysis. 
J Am Coll Cardiol . 2005;45:941-[ADDRESS_781578], Jr., Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, 
Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the sirius trial: 
A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for 
coronary restenosis. Circulation . 2004;109:634-640 
9. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo DJ, Sabaté M, Escaned J, Bañuelos 
C, Fernández-Ortiz A, Macaya C. Drug-eluting stent thrombosis: Results from a pooled analysis 
including 10 randomized studies. J Am Coll Cardiol . 2005;45:954-959 
10. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, 
Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting taxus stent: The taxus-iv trial. Circulation . 2004;109:1942-
1947 
11. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, 
Montorfano M, Carlino M, Michev I, Corvaja N, Br iguori C, Gerckens U, Grube E, Colombo A. 
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting 
stents. Jama . 2005;293:2126-2130 
12. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED, Registry. ACoCNCD. 
On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the american college of cardiology national cardiovascular data registry [ncdr]). Am J Cardiol . 
2006;97:1478-1481 
13. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, 
Berge C, Deme M, Stoll HP, Investigators. e-C. Safety of coronary sirolimus-eluting stents in 
daily clinical practice: One-year follow-up of the e-cypher registry. Circulation . 2006;113:1434-
[ADDRESS_781579] Market Study Protocol # CV103-02 Page 59 of 72 
Version 1.2 14. Daemen J, Wenaweser P, Tsuchida K, Abrecht L,  Vaina S, Morger C, Kukreja N, Juni P, Sianos 
G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. 
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in 
routine clinical practice: Data from a large two-institutional cohort study. Lancet . 2007;369:667-
678 
15. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington 
RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopi[INVESTIGATOR_592508]-term clinical outcomes after drug-eluting stent implantation. Jama . 2007;297:159-[ADDRESS_781580] B, James SK, Stenestrand U, Li ndback J, Nilsson T, Wallentin L. Long-term 
outcomes with drug-eluting stents versus bare-metal stents in sweden. N Engl J Med . 
2007;356:1009-1019 
17. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, 
Bader F, Osswald S, Kaiser C. Late clinical even ts after clopi[INVESTIGATOR_592509]-eluting stents: An observational study of drug-eluting versus bare-metal stents. J 
Am Coll Cardiol . 2006;48:2584-2591 
18. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, 
Briguori C, Sabate M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo 
A, Kirtane AJ, Leon MB, Stone GW. Stent thromb osis with drug-eluting and bare-metal stents: 
Evidence from a comprehensive network meta-analysis. Lancet . 2012;379:1393-1402 
19. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short- 
and long-term outcomes with drug-eluting and bare-metal coronary stents: A mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation . 
2012;125:2873-2891 
20. Yeh RW, Vasaiwala S, Forman DE, Silbaugh TS, Zelevinski K, Lovett A, Normand SL, Mauri L. 
Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. 
Circulation. Cardiovascular quality and outcomes . 2014;7:118-124 
21. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, 
Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after 
coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (scai). J Am Coll Cardiol . 2013;62:1563-1570 
22. Stone GW, Ellis SG, Colombo A, Grube E, Popma JJ, Uchida T, Bleuit JS, Dawkins KD, Russell 
ME. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the taxus clinical trial program. JACC: Cardiovascular interventions . 2011;4:530-[ADDRESS_781581] ent versus the driver 
bare-metal stent. 4-year results from the endeavor ii trial (randomized controlled trial to evaluate 
the safety and efficacy of the medtronic ave abt-578 eluting driver coronary stent in de novo 
native coronary artery lesions). JACC Cardiovasc Interv.  2009 2:1178-1187 
24. Fajadet J, Morice MC, Bode C, al. e. Maintenance of long-term clinical benefit with sirolimus-
eluting coronary stents. Three-year results of the ravel trial. Circulation . 2005;111:1040-[ADDRESS_781582], al. e. Five-year follow-up after sirolimus-eluting stent 
implantation. Results of the sirius (sirolimus-eluting stent in de-novo native coronary lesions) 
trial. J Am Coll Cardiol . 2009;53:1488–[ADDRESS_781583] 
Grube,Ju¨ rgen Haase,Leif Thuesen, and Christian Hamm. Five-year long-term clinical follow-up 
Medinol 
[ADDRESS_781584] Market Study Protocol # CV103-02 Page 60 of 72 
Version 1.2 of the xience v everolimus eluting coronary stent system in the treatment of patients with de novo 
coronary artery lesions: The spi[INVESTIGATOR_592510]. Catheterization and Cardiovascular Interventions . 
2010;75:997–1003 
27. Pi[INVESTIGATOR_592511], Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Mehran R, Na 
Y, Turco M, Caputo R, Popma JJ, Cutlip DE, Russell ME, Cohen DJ. Impact of routine 
angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: Results from the 
taxus-iv trial. J Am Coll Cardiol . 2006;48:32-36 
28. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Or miston J, Munzel T, Popma JJ, Fitzgerald PJ, 
Bonan R, Kuntz RE. Randomized, double-blind, multicenter study of the endeavor zotarolimus-
eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: 
Clinical and angiographic results of the endeavor ii trial. Circulation . 2006;114:798-806 
29. Stone gW, Rizvi A, Sudhir K, al. e. Randomized comparison of everolimus- and paclitaxel-
eluting stents 2-year follow-up from the spi[INVESTIGATOR_17040] (clinical evaluation of the xience v everolimus 
eluting coronary stent system) iv trial. JACC .58:19–25 
30. Wang TY, Peterson ED, Dai D, Anderson HV, Rao SV, Brindis RG, Roe MT, Registry NCD. 
Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and 
implications for the use of periprocedural myocardi al infarction as a quality metric: A report from 
the national cardiovascular data registry (ncdr). J. Am. Coll. Cardiol.  2008;51:2068-2074.  
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials . 1986;7:177-
178 
32. Moses JW, Martin B. Leon, Jeffrey J. Popma, Peter J. Fitzgerald, D avid R. Holmes, Charles 
O’Shaughnessy, Ronald P. Caputo, Dean J. Kereiakes, David O. Williams, Paul S. Teirstein, Judith L. Jaeger, Richard E. Kuntz MD, Investigators  ftS. Sirolimus-eluting stents versus standard 
stents in patients with stenosis in a native coronary artery. N Engl J Med . 2003;349:1315-1323 
33. Mehran R, Rao SV, Bhatt DL, Gibson CM, Cai xeta A, Eikelboom J, Kaul S, Wiviott SD, Menon 
V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, 
Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for 
cardiovascular clinical trials: A consensus report from the bleeding academic research 
consortium. Circulation . 2011;123:2736-[ADDRESS_781585] Market Study Protocol # CV103-02 Page 61 of 72 
Version 1.2 Appendix 1-P: Study Definitions 
ABRUPT CLOSURE 
Abrupt Closure:  Defined as the occurrence of new (during the index procedure) severely reduced 
flow (Thrombolysis in Myocardial Infarction [TIMI] grade 0–1) within the target vessel that 
persists and requires rescue by [CONTACT_13774], or results in myocardial infarction or 
death.  Abrupt closure requires proven association with a mechanical dissection of the treatment site or instrumented vessel, coronary thrombus or severe spasm.  Abrupt closure does not 
connote ‘no reflow’ (due to microvascular flow limitation), in which the epi[INVESTIGATOR_592512].  Abrupt closure also does not connote transient closure with reduced 
flow in which the index treatment application does reverse the closure.  
Subabrupt Closure:  Defined as abrupt closure that occurs after the index procedure is completed 
(and the subject has left the catheterization laboratory) and before the 30-day follow-up 
evaluation.  
Threatened Abrupt Closure:  Defined as a grade B dissection and ≥50% diameter stenosis or any 
dissection of grade C or higher. 
ACUTE SUCCESS
1  
Device Success:   Attainment of <50% residual stenosis of the target using only the NIRxcell 
Stent System.  
Lesion Success:  Attainment of <50% residual stenosis of the target lesion using any 
percutaneous method.  
Procedure Success:  Attainment of <50% residual stenosis of the target lesion and no in-hospi[INVESTIGATOR_592513], MI or TLR. 
ADVERSE DEVICE EFFECT (ADE) 
An ADE is defined as an AE related to the use of the study device. 
NOTE 1:  This definition includes AEs result ing from insufficient or inadequate 
instructions for use, deployment, implantation, installation, or operation, or any malfunction of the study device. 
NOTE 2:  This definition includes any event resu lting from user error or from intentional 
misuse of the study device. 
ADVERSE EVENT (AE) 
An AE is defined as any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users or other persons, 
whether or not related to the study device. 
NOTE 1:  This definition includes events related to the study device or the comparator. 
                                                      
1 All analyses to determine acute success measures will be conducted utilizing in-stent  residual stenosis values.  
When in-stent % residual stenosis is not available, in-lesion % residual stenosis will be used to complete the 
analysis. 
Medinol 
[ADDRESS_781586] Market Study Protocol # CV103-02 Page 62 of 72 
Version 1.2 NOTE 2:  This definition includes events related to the procedures involved. 
NOTE 3:  For users or other persons, this definition  is restricted to events related to the 
study device. 
ANTICIPATED ADVERSE EVENT  
Any undesirable experience (sign, symptom, illne ss, abnormal laboratory value or other medical 
event) occurring to a subject, whether or not considered related to the study product(s) prescribed as part of the clinical protocol, predefined in the clinical protocol and/or Instructions for Use 
(IFU), product label that is identified or worsens during a clinical study. 
BRAUNWALD CLASSIFICATION OF UNSTABLE ANGINA 
Severity 
Class 1:   New onset of severe or accelerated angina. Subjects with new onset (<2 months in 
duration) exertional angina pectoris that is severe or frequent (>3 epi[INVESTIGATOR_1841]/day) or subjects with chronic stable angina who develop accelerated angina (that is, angina distinctly more frequent, 
severe, longer in duration, or precipi[INVESTIGATOR_592514]) but who 
have not experienced pain at rest during the preceding 2 months. 
Class 2:   Angina at rest, subacute. Subjects with [ADDRESS_781587] during the 
preceding month but not within the preceding 48 hours. 
Class 3:   A n gi n a a t re s t,  ac ut e.  S u bj ec t s wi t h 1 or m ore e pi s o de s of  an gi n a at  re s t  wit hi n t he  
preceding 48 hours. 
Clinical Circumstances in Wh ich Unstable Angina Occurs 
Class A:   Secondary unstable angina. Subjects in whom unstable angina develops secondary to a 
clearly identified condition extrinsic to the coronary  vascular bed that has intensified myocardial 
ischemia.  Such conditions reduce myocardial oxygen supply or increase myocardial oxygen 
demand and include anemia, fever, infection, hypotension, uncontrolled hypertension, tachyarrhythmia, unusual emotional stress, thyrotoxicosis, and hypoxemia secondary to 
respi[INVESTIGATOR_1399]. 
Class B:  Primary unstable angina.  Subjects who develop unstable angina pectoris in the absence 
of an extracardiac condition that have intensified ischemia, as in class A. 
Class C:   Postinfarction unstable angina. Subjects who develop unstable angina within the first 2 
weeks after a documented acute myocardial infarction. 
CANADIAN CARDIOVASCULAR SOCIETY CLASSIFICATION (CCSC) OF ANGINA 
Class I:   Ordinary physical activity does not cause angina, such as walking and climbing stairs.  
Angina with strenuous or rapid or prolonged exertion at work or recreation.  
Class II:   Slight limitation of ordinary activity.  Angina upon walking or climbing stairs rapi[INVESTIGATOR_375], 
walking uphill, walking or stair climbing after meals, or in cold, wind or under emotional stress, 
or only during the first hours after awakening.  Angina if walking more than 2 blocks on the 
level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions.  
Class III:  Marked limitations of ordina ry physical activity.  Walking [ADDRESS_781588] Market Study Protocol # CV103-02 Page 63 of 72 
Version 1.2 Class IV:   Inability to carry on any physical activity without discomfort.  Angina syndrome may 
be present at rest.  
CLINICALLY DRIVEN TARGET LESION REVASCULARIZATION (TLR)  
Revascularization at the target site associated with positive functional ischemia study or ischemic 
symptoms AND an angiographic minimal lumen diameter stenosis ≥50% by [CONTACT_13775], or 
revascularization of a target site with diameter stenosis ≥70% by [CONTACT_592526] a 
positive functional study.  
CLINICALLY-DRIVEN TARGET VESSEL REVASCULARIZATION (TVR)  
Revascularization in the target vessel associated with positive functional ischemia study or 
ischemic symptoms AND an angiographic minimal lumen diameter stenosis ≥50% by [CONTACT_13775], or 
revascularization of a target vessel with diameter stenosis ≥70% by [CONTACT_13779] a positive functional study.  
CEREBROVASCULAR ACCIDENT (CVA; see Stroke )  
The occurrence of cerebral infarction (ischemic stroke) and intracerebral hemorrhage and 
subarachnoid hemorrhage (hemorrhagic stroke).  
DE NOVO  LESION  
Defined as a native coronary artery lesion not previously treated.  
DEATH  
Cardiac Death:   Any death due to proximate cardiac cause (e.g., MI, low-output failure, fatal 
arrhythmia), unwitnessed death and death of unknown cause, and all procedure-related deaths, 
including those related to concomitant treatmen t, will be classified as cardiac death.  
Vascular Death:   Death caused by [CONTACT_105]-coronary vascular causes, such as cerebrovascular 
disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm or other vascular 
diseases. 
Non-Cardiovascular Death:   Any death not covered by [CONTACT_13780], such as death 
caused by [CONTACT_80601], malignancy, sepsis, pulmonary causes, accident, suicide or trauma.  
All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. 
Specifically, any unexpected death even in subjec ts with coexisting pote ntially fatal non-cardiac 
disease (e.g., cancer, infection) should be classified as cardiac. 
DISSECTION, NHLBI (National Heart, Lung , and Blood Institute) CLASSIFICATION 
Grade A:   Small radiolucent area within the lumen of the vessel disappearing with the passage of 
the contrast material. 
Grade B:  Appearance of contrast medium parallel to the lumen of the vessel disappearing within 
a few cardiac cycles. 
Grade C:  Dissection protruding outside the lumen of the vessel persisting after passage of the 
contrast material. 
Grade D:   Spi[INVESTIGATOR_23585]-shaped filling defect with or without delayed run-off of the contrast material in 
the antegrade flow. 
Medinol 
[ADDRESS_781589] Market Study Protocol # CV103-02 Page 64 of 72 
Version 1.2 Grade E:   Persistent luminal filling defect with dela yed run-off of the contrast material in the 
distal lumen. 
Grade F:   Filling defect accompanied by [CONTACT_13784].  
EMERGENT BY[CONTACT_592547], or  treatment failure result ing in new ischemia.  
IN-SEGMENT MEASUREMENT  
Defined as the measurements either within the stented segment or within 5 mm proximal and 
distal to the stent edges.  
IN-STENT MEASUREMENT  
Defined as the measurements within the boundaries of the stent.  
LESION CLASS (American College of Cardiology/American Heart Association Class) 
Type A Lesions:  Minimally complex, discrete (length <10 mm), concentric, readily accessible, 
non angulated segment (<45°), smooth contour, little or no calcification, less than totally occlusive, not ostial in location, no major side branch involvement, and an absence of thrombus. 
Type B Lesions:  Moderately complex,  tubular (length 10–20 mm), eccentric, moderate tortuosity 
of proximal segment, moderately angulated segment (>45°, <90°), irregular contour, moderate or 
heavy calcification, total occlusions <3 months old, ostial in location, bifurcation lesions requiring double guide wires, and some thrombus present.  
Type C Lesions:   Severely complex, diffuse (length >20 mm), excessive tortuosity of proximal 
segment, extremely angulated segments >90°, total occlusions >3 months old and/or bridging 
collaterals, inability to protect major side branches, and degenerated vein grafts with friable lesions.  
MINIMAL LUMINAL DIAMETER (MLD)  
The average of 2 orthogonal views (when possible) of the narrowest point within the area of 
assessment – in-lesion, in-stent or in-segment.  MLD is visually estimated during angiography by 
[CONTACT_093]; it is measured during QCA by [CONTACT_592173].  
  
Medinol 
[ADDRESS_781590] Market Study Protocol # CV103-02 Page 65 of 72 
Version 1.2 MYOCARDIAL INFARCTION ARC Definition2 
Classification  Biomarker Criteria * Additional Criteria  
Peri- procedural PCI  Tr oponin >3 times URL or
CKMB >3 times URL Baseline value <URL 
Peri-Procedural CABG Troponin >5 times URL or 
CKMB >5 times URL Baseline value <URL AND any of the 
following: new pathologic Q waves‡ or LBBB, new native or graft vessel occlusion, imaging evidence of loss of viable myocardium  
Spontaneous 
(>48 h following PCI,  
>72 h following CABG) Troponin >URL or 
CKMB >URL. Baseline value <U RL and any o f the 
following: symptoms of ischemia, ECG 
changes indicative of new ischemia (new ST-
T changes or new LBBB), development of pathological Q waves, or imaging evidence o
f
new loss of viable myocardium or new regional wall motion abnormality. 
Silent No biomarkerdata 
available. New pathologic‡Q waves o r LBBB. 
Sudden Death Death before biomarkers 
obtained or before expected 
to be elevated. Symptoms suggestive of ischemia and any of 
the following: new ST elevation or LBBB, 
documented thrombus by [CONTACT_592548]. 
Reinfarction, spontaneous and periprocedural (base 
definition; infarction 
extension) Stable or decreasing values 
on 2 samples >6 h apart and 
20% increase  
3–6 h after second sample. If biomarkers not stable (increasing or peak 
not reached), then insufficient data to 
diagnose recurrent myocardial infarction. 
Adapted from Global Task Force Universal Definition of Myocardial Infarction, Thygesen et al. 
PCI: percutaneous coronary intervention; h: hour; URL: upper range limit (99th percentile of normal 
reference range); CKMB: creatinine kinase myocardial band isoenzyme; CABG: coronary artery by[CONTACT_4660]; LBBB: left bundle branch block; ECG: electrocardiogram.  
*Baseline biomarker value required before study procedure and presumes a typi[INVESTIGATOR_196542]. 
‡Pathologic Q waves may be defined according to the Global Task Force, Minnesota code or Novacode.  
 
NO REFLOW  
Defined as a sustained or transient reduction in antegrade flow that is not associated with an 
obstructive lesion at the treatment site.  
PERCENT DIAMETER STENOSIS  
The value calculated as 100 x (RVD – MLD)/RVD using the mean values from 2 orthogonal 
views (when possible) by [CONTACT_13775].  
                                                      
2 Cutlip DE, Windecker S, Mehran R et al. for the Academic Research Consortium. Clinical endpoints in coronary 
stent trials: A case for standardized definition. Circulation  2007;115:2344–2351. 
Medinol 
[ADDRESS_781591] Market Study Protocol # CV103-02 Page 66 of 72 
Version 1.2 PERFORATION  
Perforations will be classified as follows:  
Angiographic perforation:  perforation detected by [CONTACT_592549]. 
Clinical perforation:  perforation requiring additional treatm ent (including efforts to seal the 
perforation or pericardial drainage), or resulting in significant pericardial effusion, abrupt closure, myocardial infarction, or death. 
Pericardial hemorrhage/tamponade:  perforation resulting in cardiac tamponade.  
PERCUTANEOUS CORONARY INTERVENTION (PCI)  
Refers to all interventional cardiology methods for treatment of coronary artery disease.  
RESTENOTIC LESION  
Defined as a lesion in a vessel segment that has undergone prior percutaneous treatment with or 
without a stent placement.   
REFERENCE VESSEL DIAMETER (RVD)  
Defined as the average of normal segments within 10 mm proximal and distal to the target lesion 
from 2 orthogonal views using QCA.   
SERIOUS ADVERSE EVENT (SAE)  
A Serious Adverse event (SAE) is any AE event that leads to: 
1. Death, 
2. Serious injury that : 
a. Is life-threatening illness or injury 
b. Results in permanent impairment of a body  function or permanent changes to a body 
structure or 
c. Necessitates medical or surgical intervention  to preclude permanent impairment of a 
body function or permanent damage to a body function. 
NOTE 1:  Planned hospi[INVESTIGATOR_5912]-existing condition, or a procedure required by [CONTACT_478160], and not meeting any of the serious criteria described above  , is not 
considered to be an SAE.  A planned hospi[INVESTIGATOR_592501]. 
STENT THROMBOSIS - ARC DEFINITION  
Stent thrombosis should be reported as a cumulative value at the different time points and with 
the different separate time points.  Time [ADDRESS_781592] has left the catheterization lab. 
Timing 
 Acute stent thrombosis*  [ADDRESS_781593]–stent implantation 
 Subacute stent thrombosis*  >[ADDRESS_781594]–stent implantation 
Medinol 
[ADDRESS_781595] Market Study Protocol # CV103-02 Page 67 of 72 
Version 1.2  Late stent thrombosis†   [ADDRESS_781596]–stent implantation 
 Very late stent thrombosis†  >[ADDRESS_781597]–stent implantation 
*Acute/subacute can also be replaced by [CONTACT_196591].  Early stent 
thrombosis (0–30 days) is a definition currently used in the community. 
†Including primary as well as secondary late stent thrombosis.  Secondary late stent 
thrombosis is a stent thrombosis afte r a target segment revascularization. 
Categories (Definite, Probable, and Possible) 
Definite Stent Thrombosis 
Definite stent thrombosis is cons idered to have occurred by [CONTACT_592550]. 
Angiographic Confirmation of Stent Thrombosis* 
Presence of an intracoronary thrombus that originates in the stent or in the segment [ADDRESS_781598] 1 of the following criteria within a 
48-hour time window: 
 Acute onset of ischemic symptoms at rest. 
 New ischemic ECG changes that suggest acute ischemia. 
 Typi[INVESTIGATOR_196543] (refer to definition of spontaneous MI). 
Non-occlusive:  intracoronary thrombus is defined as a spheric, ovoid, or irregular non-
calcified filling defect or lucency surrounded by [CONTACT_13800] (on 3 sides or within a 
coronary stenosis) seen in multiple projections , or persistence of contrast material within 
the lumen, or a visible embolization of  intraluminal material downstream. 
Occlusive Thrombus:  TIMI [ADDRESS_781599] 
adjacent proximal side branch or main branch (if originates from side branch). 
Pathological Confirmation of Stent Thrombosis 
Evidence of recent thrombus within the stent determined at autopsy or via examination of 
tissue retrieved following thrombectomy. 
*The incidental angiographic documentation of stent occlusion in the absence of clinical signs or symptoms 
is not considered a confirmed stent thrombosis (silent occlusion). 
Probable Stent Thrombosis 
Probable stent thrombosis is considered to have  occurred after intracoro nary stenting in the 
following cases: 
 Any unexplained death within first 30 days.† 
 Regardless of time after index procedure, any MI related to documented acute ischemia 
in the territory of the implanted stent w ithout angiographic confirmation of stent 
thrombosis and in the absence of any other obvious cause. 
†For studies with ST-elevation MI population, exclusion of unexplained death within [ADDRESS_781600] Market Study Protocol # CV103-[ADDRESS_781601] occurred with any unexplained death from  
30 days after intracoronary stenting until end of trial follow-up. 
STROKE  
Defined as sudden onset of vertigo, numbness, dysphasia, weakness, visual field defects, 
dysarthria or other focal neurological deficits due to vascular lesions of the brain such as hemorrhage, embolism, thrombosis, or rupturing aneurysm, that persists >[ADDRESS_781602] the study according to the 
clinical protocol or the investigator agreement.   
Major deviation:  any deviation from subject inclusion and exclusion criteria or subject informed 
consent procedures. 
Minor deviation:  deviation from a clinical protocol requirement such as incomplete/inadequate 
subject tests or examinations, non-compliance with medication regimens, missed follow-ups, 
follow-ups performed outside specified time windows, etc. 
TARGET LESION  
The lesion intended to be treated with the treatment device.  
TARGET LESION REVASCULARIZATION (TLR)  
TLR is defined as any percutaneous intervention of the target lesion or by[CONTACT_592551].  All TLRs 
should be classified prospectively as clinically indicated or not clinically indicated by [CONTACT_592552].  An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication 
and will overrule in cases in which investigator re ports are not in agreement.  The target lesion is 
defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent. 
TARGET VESSEL FAILURE (TVF)  
Defined as a composite of cardiac death, target vessel myocardial infarction (MI), or clinically 
driven target vessel revascularization (TVR) by [CONTACT_13724].  
TARGET VESSEL REVASCULARIZATION (TVR)  
TVR is defined as any percutaneous intervention or surgical by[CONTACT_478191].  The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches and the target lesion itself. 
THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) CLASSIFICATION  
TIMI 0:  No perfusion.  
TIMI 1:  Penetration with minimal perfusion.  Contrast fails to opacify the entire bed distal to the 
stenosis for the duration of the cine run.  
TIMI 2:  Partial perfusion.  Contrast opacifies the entire coronary bed distal to the stenosis.  
However, the rate of entry and/or clearance is slower in the coronary bed distal to the obstruction 
than in comparable areas not pe rfused by [CONTACT_306100].  
Medinol 
[ADDRESS_781603] Market Study Protocol # CV103-02 Page 69 of 72 
Version 1.2 TIMI 3:  Complete perfusion.  Filling and clearance of contrast equall y rapid in the coronary bed 
distal to stenosis as in other coronary beds.  
TRANSIENT ISCHEMIC ATTACK (TIA)  
Defined as sudden onset of vertigo, numbness, dysphasia, weakness, visual field defects, 
dysarthria or other focal neurological deficits due to vascular lesions of the brain such as hemorrhage, embolism, thrombosis, or rupturing aneurysm, that persists <[ADDRESS_781604] (UADE)  
A UADE is defined in 21 CFR 812.3(s) as any serious adverse effect on health or safety or any 
life-threatening problem or death caused by, or associated with, a device, if that effect, problem, 
or death was not previously identified in nature, severity or degree of incidence in the protocol, or any other unanticipated serious problem associated with a device that relates to the rights, 
safety, or welfare of a subject.  
Medinol 
[ADDRESS_781605] Market Study Protocol # CV103-02 Page 70 of 72 
Version 1.2 ACRONYMS AND/OR ABBREVIATIONS 
Acronym/ 
Abbreviation Term 
ACE-I Angiotensin converting enzyme inhibitor 
ACT Activated clotting time 
ADE Adverse device effect AE Adverse event 
APTT Activated partial thromboplastin time 
ARB Angiotensin receptor blocker ARC Academic Research Consortium 
atm Atmospheric pressure 
AVF Arteriovenous fistula 
BMI Body mass index 
BMS Bare metal stent 
CABG Coronary artery by[CONTACT_592553]é Européenne 
CEC Clinical Events Committee 
CFR Code of Federal Regulations CI Confidence interval 
CK Creatine kinase CK-MB Creatine kinase myocardial-band isoenzyme 
cm Centimeter 
CoCr Cobalt-chromium 
CRO Contract research organization CT Computed tomography 
CVA Cerebrovascular accident 
DAPT Dual antiplatelet therapy 
DES Drug-eluting stent dL Deciliter 
ECG Electrocardiogram eCRF Electronic case report form 
EDC Electronic data capture 
ETT Exercise tolerance test 
Medinol 
[ADDRESS_781606] Market Study Protocol # CV103-02 Page 71 of 72 
Version 1.2 Acronym/ 
Abbreviation Term 
FDA Food and Drug Administration 
GCP Good Clinical Practices 
GI Gastrointestinal HCRI Harvard Clinical Research Institute 
HIPAA Health Insurance Portability and Accountability Act IC Informed consent 
ICF Informed consent form 
ICH International Conference on Harmonisation  
IFU Instructions for Use 
INR International normalized ratio 
IRB Institutional Review Board 
ITT Intention-to-treat K-M Kaplan-Meier 
LAD Left anterior descending coronary artery LBBB Left bundle branch block 
LCX Left circumflex coronary artery 
LIMA Left internal mammary artery 
LVEF Left ventricular ejection fraction MACE Major adverse cardiac event 
MDR Medical device reporting mg Milligram 
MI Myocardial infarction 
MLD Minimum luminal/lumen diameter mm Millimeter 
NHLBI National Heart, Lung, and Blood In stitute [Dissection Grade Classification] 
NQWMI Non–Q-wave myocardial infarction 
NTG Nitroglycerin 
PCI Percutaneous coronary intervention PG Performance goal 
PMA Premarket approval PP Per-protocol 
PTCA Percutaneous transluminal coronary angioplasty 
QCA Quantitative coronary angiography 
QWMI Q-wave myocardial infarction 
Medinol 
[ADDRESS_781607] Market Study Protocol # CV103-02 Page 72 of 72 
Version 1.2 Acronym/ 
Abbreviation Term 
RIMA Right internal mammary artery 
RVD Reference vessel diameter 
SAE Serious adverse event SAS Statistical analysis system 
SOP Standard operating procedure SPECT Single-photon emission computed tomography 
TIA Transient ischemic attack 
TIMI Thrombolysis in Myocardial Infarction 
TLR Target lesion revascularization 
TVF Target vessel failure 
TVR Target vessel revascularization 
UADE Unanticipated adverse device effect ULN Upper limit of normal 
URL Upper reference limit US [LOCATION_002] 
[LOCATION_003] [LOCATION_002] of America 
WBC White blood cell 
 
 